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Pyruvate kinase deficiency (PKD) is the main cause of chronic non-spherocytic 
hemolytic anemia. This disease is a monogenic recessive disorder that occurs due to 
mutations in PKLR gene. Although this gene codifies the expression of two isoforms of 
pyruvate kinase, expressed in liver and in red blood cell s, only the erythroid lineage is 
affected. Pyruvate kinase is the enzyme that catalyzes the last step of the glycolysis, a 
critical exergonic reaction for the energetic survival of erythrocytes.  
Due to its low prevalence (about 5:20,000), PKD is considered a rare disease. 
Severity of the disease is variable, ranging from mild cases, having hemoglobin levels around 
11 g/dL and requiring blood transfusions just during exacerbations, to values below 8.5 g/dL 
in the most severe cases, being transfusion-dependent and fatal in the worst cases. Most 
severe cases are transfusion-dependent even after splenectomy, the most agresive palliative 
treatment. 
Apart from palliative treatments, such as blood transfusions or splenectomy, the 
only existing curative treatment is the allogenic bone marrow transplantation. But this 
strategy has important limitations, such as the lack of histocompatible donors, the reject of 
the engraftment or the dangerous graft versus host disease. Gene therapy is a strategy that 
can solve all these limitations since it is based on the autologous transplantation of 
hematopoietic progenitors genetically corrected. 
Regarding gene therapy approach, our group has shown PKD correction in a mouse 
model of the disease using a lentiviral-based gene therapy. The results of these pre-clinical 
trials allowed us to apply for orphan drug designation, obtaining it from EMA (European 
Medicines Agency) and from FDA (Food and Drug Administration) in 2014 and 2016, 
respectively. 
The main objectives of this work were i) to continue studying the extent of 
hematopoietic alterations in PKD patient samples obtained from the physicians, especially 
regarding erythroid lineage; ii) more directly associated with the gene therapy program, to 
explore the limiting dose of corrected cells capable of rescuing the PKD phenotype in a 
mouse model; and iii) due to the difficulties to obtain PKD hematopoietic progenitors in 
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which to test gene therapy tools, the aim was the generation of PKD-like cells from healthy 
hematopoietic progenitors using two different approaches, mRNA disruption based on short 
hairpin RNAs and direct genome editing based on CRISPR/Cas9 system. 
A complete analysis of peripheral blood samples from PKD patients, through the 
complete blood count and flow cytometry immunophenotyping, was performed. Erythroid 
lineage of patients was the most affected subset, showing an increase in erythroid progenitor 
population and in reticulocytes, a clear signal of the response of the bone marrow to the 
anemic stress. A deeper study to clarify the possible affectation of primitive hematopoietic 
progenitors in this disease was carried out based on colony forming unit assays and flow 
cytometry of CD34+ marker. There was a small but not significant increase of hematopoietic 
progenitors in peripheral blood of PKD patients. Also, PK deficient CD34+ hematopoietic 
progenitor cells from patients did not show impairments generating these colonies in semi 
solid media, meaning that these progenitors were not distinguishable from healthy 
progenitors. Furthermore, data collected from patients’ relatives, which had loss of one 
PKLR functional allele, showed a decrease of erythroid parameters but not enough to reach 
an anemic situation. Nevertheless, the number of relatives studied was low, so these results 
must be carefully interpreted.  
Regarding the limiting dose of cells corrected with our therapeutic lentiviral vector 
necessary to correct deficient features, conditioned PKD mice were transplanted with PKD 
hematopoietic progenitors transduced at different doses of viral vector. The number of 
transgene copies present in peripheral blood was evaluated and correlated with the 
hematologic profile. PKD phenotype was corrected when the number of transgene copies 
per cell was higher than 0.3 in mice peripheral blood. These results allow us to set a 
therapeutic threshold above which transduction efficacies must aim to ensure the feasibility 
of the gene therapy treatment of PKD patients in the clinical trial scenario. 
The generation of human PKD-like cells that recapitulate the disease features was 
carried out by shRNAs and CRISPR/Cas9 system.  
With respect to the shRNA approach, hematopoietic progenitors from healthy 
donors were transduced with shRNA lentiviral vectors and differentiated in vitro towards 
erythroid lineage. The use of non-transduced and shRNA transduced cells in the same well 
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allowed us to observe an alteration in normal cell growth of the shRNA transduced cells, 
which also occurred with the control shRNA. Nevertheless, sorting-based selection of 
transduced cells permitted the enrichment of this population and the confirmation of the 
model by the evaluation of the decrease of pyruvate kinase activity. 
In the same way, hematopoietic progenitors from healthy donors were modified by 
CRISPR/Cas9 technology. Different locations of PKLR gene, first exons 8, 9 and 11, and 
afterwards different regions from exon 9 to 10, were selected to be altered by Cas9 nuclease 
action. These hematopoietic progenitors were electroporated with Cas9 nuclease and 
specific guideRNAs for the regions previously commented. The use of exon 9 as target for 
Cas9 action completely eliminated RPK protein production, showing the importance of this 
region for generation of the enzyme. To control the outcomes of the genome editing 
process, guides were used in couples, generating a predictable precise deletion pattern as the 
most represented event. These human PKD-like cells were differentiated in vitro towards 
erythroid lineage, demonstrating, finally, the decrease of pyruvate kinase activity in these 
mature PKD-like cells, not finding alterations along in vitro erythroid differentiation and 
being, therefore, an appropriated and novel model to test new advanced therapies for PKD. 
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La deficiencia en piruvato quinasa (PKD, por sus siglas en inglés) es la principal 
causa de anemia hemolítica no esferocítica. Es una enfermedad monogénica-recesiva que se 
origina por mutaciones en el gen PKLR. Aunque este gen codifica la información para la 
producción de dos isoformas de piruvato quinasa, expresadas en hígado y en eritrocitos, solo 
el linaje eritroide se ve afectado. La piruvato quinasa es la enzima que cataliza la última 
reacción de la glicólisis, un proceso exergónico crucial para la supevivencia energética de los 
eritrocitos. 
Dada su baja prevalencia (alrededor de 5 de cada 20.000 habitantes), PKD es 
considerada una enfermedad rara. La severidad de la enfermedad es variable, desde casos 
leves con niveles de hemoglobina de 11 g/dL que solo necesitan transfusiones de eritrocitos 
puntuales durante exacerbaciones de la enfermedad, hasta casos graves con niveles de 
hemoglobina inferiores a 8.5 g/dL, dependientes de transfusiones periódicas que incluso 
pueden causar la muerte. Los casos más severos son dependientes de transfusiones periódicas 
incluso después de ser esplenectomizados, el tratamiento paliativo utilizado más agresivo. 
Al margen de los tratamientos paliativos, como transfusiones y la esplenmectomía, 
solo existe un tratamiento curativo, el trasplante alogénico de médula ósea. Pero este 
procedimiento tiene importantes limitaciones, como son la dificultad de encontrar donantes 
compatibles, la posibilidad de rechazo del injerto o la enfermedad de injerto contra huésped. 
La terapia génica es una estrategia que solventaría estas limitaciones ya que se basa en el 
trasplante autólogo de progenitores hematopoyéticos genéticamente corregidos. 
Respecto a la aproximación de terapia génica, nuestro grupo demostró corrección de 
la enfermedad en un modelo múrido de PKD corrigiendo mediante el uso de un vector 
lentiviral. Estos ensayos preclínicos nos permitieron la aprobación del vector como 
medicamento huérfano por la las agencias europea y americana del medicamento (EMA; 
European Medicines Agency y FDA; Food and Drug Administration) en 2014 y 2016 
respectivamente. 
Los principales objetivos de este trabajo han sido i) continuar estudiando el alcance 
de las alteraciones hematopoyéticas en muestras de pacientes, especialmente en el linaje 
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eritroide; ii) más directamente relacionado con el programa de terapia génica, el objetivo fue 
averiguar la cantidad mínima de células corregidas capaz de rescatar el fenotipo PKD en un 
modelo de ratón; y iii) debido a las dificultades en la obtención de muestras de progenitores 
hematopoyéticos deficientes, el objetivo fue la generación de células deficientes en PK a 
partir de progenitores hematopoyéticos procedentes de donantes sanos mediante la 
utilización de dos aproximaciones diferentes, eliminación de ARN mensajero mediante 
shRNA, y edición directa del genoma mediante el sistema CRISPR/Cas9. 
Se analizaron muestras de sangre periférica de los pacientes de PKD mediante 
hemograma e inmunofenotipo utilizando citometría de flujo. El linaje más afectado fue el 
eritroide, mostrando un gran incremento del número de progenitores eritroides y 
reticulocitos circulantes, una clara señal de la respuesta de la médula ósea al estrés producido 
por la situación anémica. Igualmente, se llevó a cabo un estudio más exhaustivo de la posible 
afectación de los progenitores hematopoyéticos más primitivos a través del ensayo de 
unidades formadoras de colonias y del marcaje de CD34+ en las células circulantes. Estos 
experimentos mostraron un pequeño, aunque no significativo, aumento del número de 
células CD34+ en el torrente sanguíneo de los pacientes con respecto a los donantes sanos. 
Además, los progenitores hematopoyéticos deficientes no mostraron peor capacidad de 
generación de colonias en cultivos semi-sólidos que sus homólogos de donantes sanos. Los 
valores obtenidos de la sangre periférica de familiares de pacientes, que solo tenían afectos 
uno de los alelos, estaban ligeramente disminuidos pero no lo suficiente como para llegar a 
una situación de anemia. En cualquier lugar, el número de muestras de familiares analizadas 
fue demasiado bajo por lo que estos resultados se han de tomar con cautela. 
Respecto al número mínimo de células corregidas necesario para restaurar valores 
sanos en el modelo animal el planteamiento fue el siguiente. Ratones PKD acondicionado 
fueron trasplantados con progenitores hematopoyéticos que previamente habían sido 
transducidos con diferentes dosis del vector terapéutico. El número de copias de transgén 
fue evaluado en las células presentes en la sangre periférica y este resultado se correlacionó 
con el nivel de corrección de la enfermedad alcanzado en cada caso. El fenotipo deficiente 
fue corregido en los ratones que tenían al menos 0,3 copias de vector por célula. Este 
resultado nos ha permitido establecer un umbral por encima del cual deben permanecer los 
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niveles de transducción para hacer posible el tratamiento de PKD mediante terapia génica de 
cara a un futuro ensayo clínico. 
La generación de células humanas PKD a partir de progenitores hematopoyéticos 
sanos se llevó a cabo mediante el uso de shRNA y el sistema CRISPR/Cas9. 
En la aproximación con shRNA, progenitores hematopoyéticos de donantes sanos 
fueron transducidos con vectores lentivirales conteniendo shRNAs y fueron diferenciados 
hacia linaje eritroide. El cultivo conjunto de células transducidas y no transducidas nos 
permitió comprobar que los vectores utilizados ralentizaban el crecimiento de las células 
transducidas, incluidas las que lo habían sido con el vector control. En cualquier caso, la 
separación de las células transducidas mediante “cell sorting” permitió el enriquecimiento de 
la población rica en shRNA, así como la confirmación de estas células como deficientes en 
actividad piruvato quinasa mediante el análisis de actividad enzimática específico.  
Un procedimiento similar se llevó a cabo en el caso del sistema CRISPR/Cas9. 
Diferentes regiones del gen PKLR, en un principio los exones 8, 9 y 11 y posteriormente 
regiones comprendidas entre los exones 9 y 10, fueron las elegidas para que actuara la 
nucleasa Cas9. Progenitores hematopoyéticos procedentes de donantes sanos fueron 
electroporados con la nucleasa y con las guías de RNA específicas para las regiones 
previamente comentadas. El uso del exón 9 como objetivo eliminó completamente la 
producción de la enzima, demostrando la importancia de dicha región para la proteína. Las 
guías fueron utilizadas en parejas para tener un mayor control sobre los eventos de 
reparación del ADN, ya que de este modo producían en su mayoría un patrón de eliminación 
de nucleótidos predecible. Estos progenitores modificados fueron diferenciados hacia linaje 
eritroide, demostrando finalmente un descenso de la actividad PK tras la edición del genoma 
y su capacidad para diferenciarse hasta los estadios más maduros. Estas propiedades hacen de 
estas células un modelo humano novedoso y útil en el que probar nuevas terapias para el 
tratamiento de PKD. 
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293T Human Embryonic Kidneys (HEK) Transformed With Large T Antigen. 
2-PG 2-Phosphoglycerate 
3-PG 3-Phosphoglycerate 
aa Amino Acid 
ADP Adenosine Diphosphate 
AMP Adenosine Monophosphate 
ATP Adenosine Triphosphate 
BFU-E Burst-Forming Unit-Erythroid 
BPGM Biphosphoglycerate Mutase 
BSA Bovine Serum Albumin 
CFU-E Colony-Forming Unit–Erythroid 
CFU-GM Colony Forming Unit Granulocyte-Macrophages  
CMP Common Myeloid Progenitor 
CNSHA Chronic Non-Spherocytic Hemolytic Anemia  
CRISPR/Cas9 Clustered Regularly Interspaced Short Palindromic Repeats/ Cas9 
CytB5R NADH-Cytochrome B5 Reductase 
DMEM Dulbecco’s Modified Eagle´S Medium  
DSB Double Strand Break 
EF1 Elongation Factor-1 Alpha  
EMP Erythoblast-Macrophage Protein 
EryD Definitive Erythroid Cells 
EryP Primitive Erythroid Cells 
FBP Fructose-1,6-Bisphosphate  
FLI-1 Friend Leukemia Integration 1 Transcription Factor 
G6P Glucose-6-Phosphate 
GATA-1  GATA binding protein 1 
GMP Granulocyte-Macrophage Progenitors  
GSH Glutathione 
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GSSG Glutathione Disulphide 
GVHD Graft Versus Host Disease 
H2O2 Hydrogen Peroxide 
Hb Hemoglobin 
HK Hexokinase 
HSC Hematopoietic Stem Cell 
HSCT Hematopoietic Allogeneic Stem Cell Transplantation 
ICAM4 Intracellular Adhesion Molecule 4  
IGF-1 Insulin-like Growth Factor-1 
IMDM Iscove´S Modified Dulbeco´S Medium 
IMS Immunomagnetic Separation 
iPSCs Induced Pluripotent Cells 
KLF1 Kruppel Like Factor 1 
LCL  Lymphoblastoid Cell Line 
LPK Liver Pyruvate Kinase  
M Missense Mutation 
MCH Mean Corpuscular Hemoglobin 
MCV Mean Corpuscular Volume 
MEP Megakaryocytic-Erythroid Progenitor (MEP) 
mHb Methemoglobin 
MIT Massachusetts Institute of Technology 
MLP Multipotent Lymphoid Progenitor 
MM Mismatches 
MOI Multiplicity of Infection 
MPP Multipotential Progenitor Cell 
NADH Nicotinamide Adenine Dinucleotide 
NADPH Nicotinamide Adenine Dinucleotide Phosphate 
NGS Next Generation Sequencing  
NM Non-Missense Mutation 
PAM Protospacer Adjacent Motif 
PBS Phosphate-Buffered Saline 
PEP Phosphoenolpyruvate  
Abbreviations 
 
9 
 
PFK-1 Phosphofructokinase 1 
PGI Phosphoglucose Isomerase 
PGK Phosphoglycerate Kinase Promoter 
PK Pyruvate Kinase  
PKD Pyruvate Kinase Deficiency 
PMCA Plasma Membrane Ca2+-ATPase 
PU.1  PU-Box Binding Site, A Purine-Rich DNA Sequence 
qPCR Quantitative PCR  
RBC Red Blood Cells 
ROC  Receiver Operating Characteristic 
RPK Red Blood Cell Pyruvate Kinase  
RPMI Roswell Park Memorial Institute 
Scrb Scramble 
SFFV Spleen Focus-Forming Virus 
shRNA Short Hairpin RNA  
TALEN Transcription Activator-Like Effector Nucleases 
TFRC Transferrin Receptor 1  
TSS Transcription Start Site  
TU Transducing Units 
VCAM-1 Vascular Cell Adhesion Molecule-1  
VCN Vector Copy Number 
Wpre Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Element 
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Along this thesis manuscript different subjects will be discussed, all of them having a 
rare disease in common, pyruvate kinase deficiency (PKD). PKD is produced by mutations 
in PKLR gene, which encodes liver and red blood cell isoforms of pyruvate kinase (LPK and 
RPK, respectively). The disease appears when mutations affect RPK activity which 
dramatically impairs red blood cell lifespan.  
To be aware when RPK takes importance for erythroblast´s life, a general overview 
of erythropoiesis is about to be explained at the beginning of this introduction. Then, RPK 
will be introduced by a brief explanation about the protein structure, gene structure and 
gene regulation. To further visualize the problem that a defective RPK can be, a short 
review of the erythrocyte´s metabolic processes will be presented highlighting the steps in 
which pyruvate kinase (PK) acts as keystone of red blood cells (RBC) survival. Also, a 
review of the disease, diagnosis and available treatments, including future ones as gene 
therapy and gene editing, are going to be explained. 
 
Hematopoiesis is a sequential process based on the self-renewal/differentiation 
equilibrium. All blood lineages arise from the same cell type, the hematopoietic stem cell. 
As long as cells acquire a more committed profile to a specific lineage, they lose their self-
renewal capability and their chance of differentiate to other lineages (Figure  1). 
Hematopoiesis can be classified in two big lineages, lymphoid (that include B and T 
lymphocytes, natural killer cells) and myeloid (that includes granulocytes, platelets and 
erythrocytes). Other hematopoietic cells such as dendritic cells and monocytes can mature 
from common myeloid progenitor but also from myeloid-lymphoid progenitors, 
exemplifying the dynamic equilibrium among lineages.1  
Erythropoiesis  
1. Primitive and definitive erythropoiesis	
There are two well differentiated types of erythropoiesis: primitive (EryP) and 
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definitive (EryD). Although both types share some basic features, they arise from different 
mesoderm populations of the embryo.2 
In the first wave of hematopoiesis, detectable after the 3rd week of gestation, EryP 
provides oxygen to the embryo during its rapid growth phases. Primitive erythroid 
progenitors are different from the definitive counterpart. They are bigger and express 
different globin genes than the definitive ones.3 EryP is produced in the yolk sac and egress 
to the circulation nucleated mostly composed by erythroid cells. Unlike in the case of 
reptilian and avian erythrocytes, mammalian EryP nuclei are eventually expelled as they 
circulate.4 
In humans, the second hematopoietic wave begins in the yolk sac at week 4. This 
second wave is composed by erythroid and myeloid cells. Fetal liver hematopoiesis becomes 
active contributing to the already active yolk sac hematopoiesis by weeks 5-6. EryP and 
EryD coexist at this stage. Then, EryD population rises becoming the main source of 
hematopoietic progenitors, throughout the rest of the fetal life.2 
Finally, in the third wave, the hematopoiesis migrates to seed the thymus and bone 
marrow reaching the final niche of mature hematopoiesis. At birth, EryD is produced in 
bone marrow being, hereby, the source of all hematopoiesis throughout the adult life-
span.2,5 
2. Erythroid differentiation in definitive erythropoiesis 	
Depending on the ability to self-renewal and to differentiate into one or multiple 
hematopoietic lineages, progenitors committed towards erythroid lineage have been 
classified as follows (Figure 1). 
Multipotent progenitor (MPP) cells are primitive progenitors still capable of 
generating all type of hematopoietic cells. Although molecular changes that determine 
whether MPP cells become erythroid progenitor are not completely clear, it is known that 
an increase in the transcription factor PU.1 promotes the differentiation towards common 
myeloid progenitors (CMP) that have lost the ability to give rise to lymphoid cells. Then, 
zinc finger transcription factor GATA-1 makes possible the differentiation toward the 
erythroid lineage, reaching the megakaryocytic-erythroid progenitor (MEP) stage. Finally, 
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two transcription factors, KLF1 and FLI-1, compete to differentiate MEP into either 
erythroid or megakaryocyte cells, respectively.6 
 
Figure 1. Hematopoiesis hierarchy. 
Hematopoietic stem cell (HSC), multipotent progenitor (MPP), multipotent  lymphoid progenitor (MLP), 
common  myeloid  progenitors  (CMP),  granulocyte‐macrophage  progenitors  (GMP),  megakaryocytic‐
erythroid progenitor  (MEP). Red asterisk  label the beginning of erythroid differentiation, which occurs 
mainly on blood islands.1 
 
After MEP, eight different developmental stages along definitive erythroid 
maturation have been described. Similar to the above mentioned, all of them allocate also in 
the bone marrow except the two final cell types (reticulocytes and mature erythrocytes), 
that circulate in the blood stream.  
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The most immature progenitor of the erythroid specific compartment is called 
Burst-forming unit-erythroid (BFU-E). These progenitors receive their name from their 
behavior forming colonies in semisolid media. After 14 days of in vitro culture, human BFU-
Es appear as colonies with a central core, surrounded by smaller satellite clusters in a “burst” 
shape. Transferrin receptor 1 (TFRC, also called CD71), necessary for transporting the iron 
which afterwards will be part of heme group, begins to be expressed at the end of this 
stage.7,8 
Thereafter, the next identified differentiation step is the named Erythroid-Colony 
Forming Unit (CFU-E). They are also defined because of its in vitro growth in semi-solid 
media. Human CFU-Es are small erythroid colonies that are observable after 5-7 days in 
culture. Survival of this cell type is strictly dependent of erythropoietin (EPO) and high 
levels of this molecule induce differentiation to more committed steps.3 CFU-Es are also 
capable to adhere to the macrophage surface. This property makes possible the formation of 
the structure where the next steps of erythroid differentiation take place, the so called blood 
island.5,6 
The basic organization of a blood island is a central macrophage surrounded by as 
many as 30-48 erythroid committed cells.6,9 This cell-cell contact is necessary for the correct 
maturation of the erythroid progenitors toward the erythroblast state. The first interaction 
occurs thanks to the action of erythroblast-macrophage protein (EMP). EMP is present on 
both erythroblasts and macrophages and is in charge of the initial joining. But not only EMP 
ensures macrophage-erythroblast interaction. Erythroid precursors start to express several 
adhesion proteins such as 41 integrin and intracellular adhesion molecule 4 (ICAM4) 
which interact with vascular cell adhesion molecule-1 (VCAM-1) and αV integrins 
respectively, present on macrophages.10 The presence of 41 and 51 integrins decrease 
over maturation to make easy the egress of mature erythroblasts.11 Other adhesion proteins 
found in central macrophages, such as CD169 and CD163, have been described to play a role 
in the blood islands.10 For example, it has been studied that CD163 scavenges hemoglobin–
haptoglobin complexes from the circulation, being important in hemoglobin homeostasis.12  
These macrophages also have a key role in the last stage of maturation, being the 
cells that must help to remove and degrade the nuclei from orthochromatic erythroblasts. 
Macrophages recognize protein S bound to the phosphatidylserines present in the surface of 
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the nucleus, here called pyrenocyte, through their Mer tyrosine kinase receptor.9 After this 
recognition, nuclei are phagocyted by the central macrophage turning orthochromatic 
erythroblast into reticulocytes. Macrophages, equipped with high levels of DNase II, recycle 
the ingested DNA and facilitate the enucleated egression of the reticulocyte to the 
peripheral blood.4 It is known that this is a fast process that occurs within 10 minutes. 
Another important central macrophage function is the direct transfer of iron to the 
erythroblasts.12  
Along their maturation in the blood islands, erythroblasts are classified as follows: 
Pro-erythroblast. It has 20-25 m of diameter and its nucleus occupies 
approximately 80% of cell area. Pro-erythroblasts present a slightly oval shape and have a 
characteristic intense basophilic cytoplasm due to the high polyribosome concentration. 
Moreover, ferritin and hemoglobin are already present at this stage. 
Basophilic erythroblast. Along differentiation the cell size decreases. The mean 
diameter is 17 m and their nuclei occupy about 75% of cell surface. It exhibits a dark violet 
chromatin with pink-stained clumps and like its predecessor shows a strong basophilic 
cytoplasm. 
Polychromatophilic erythroblast. After mitotic division, basophilic erythroblast turns 
into polychromatophilic erythroblast. The new cell type suffers some changes: the diameter 
decreases until 13 m, and its nucleus occupies less than 50% of the surface. The increase of 
hemoglobin decreases the polyribosome basophilia turning the cytoplasm in gray color. In 
this stage, CD71 expression reaches its maximum levels all over the maturation.7 
Additionally, polychromatophilic erythroblasts carry out the last mitotic division of the 
erythroid maturation. 
Orthochromatic erythroblast. Cell diameter decreases to 10-15 m and its nucleus 
occupies only a quarter of cell surface. Furthermore, nucleus shows a polarized distribution 
along the cytoplasm, preparing the enucleation. Orthochromatic erythroblast shows big 
motility capacity, probably necessary for nucleus ejection. Hemoglobin staining is 
predominant, and this is the last erythroblast bound to blood islands.  
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Reticulocyte. Orthochromatic erythroblast divides itself in reticulocyte and 
pyrenocyte (nucleus) helped by the macrophages. It receives its name because the rests of 
mitochondria, polyribosomes, Golgi apparatus and other organelles give it a reticular aspect. 
Reticulocyte matures in approximately 48-72 hours. During reticulocyte maturation, 
polyribosomes stop protein production and separate into monoribosomes. Cell size 
decreases, membrane structure is remodeled and gradually loses CD71. These changes make 
it more elastic and stable.  
Mature erythrocyte. Finally, the mature erythrocyte with its classical biconcave 
shape arises out from the reticulocytes. It is the smallest erythroid cell, around 7.5 m, and 
its membrane is prepared to be extremely deformable. This feature allows them to enter into 
capillaries of 2.8 m diameter to transport oxygen anywhere. Their lifespan is around 100-
120 days and its cell surface decreases over time. This decrease (up to 20% of its area) is 
related with cell ageing, producing a decrease in their deformability and, hence, an 
impairment of oxygen delivery. To maintain the normal amount of erythrocytes (5 x 106 
RBC/l), 2 x 1011 new erythrocytes need to be produce every day.5,6,13 
 
Red blood cell pyruvate kinase  
 
1. Protein structure and regulation	
Pyruvate kinase catalyzes the final irreversible reaction of anaerobic glycolysis, also 
known as Embden–Meyerhof pathway, transforming phosphoenolpyruvate (PEP) into 
pyruvate. The energy released in this reaction is used to transform adenosine diphosphate 
(ADP) into adenosine triphosphate (ATP).14 Pyruvate is the first non-phosphorylated 
intermediate and plays a central role in metabolism. PK activity requires two divalent 
cations, usually Mg2+, and a monovalent cation, normally K+.15 
PK is an enzyme largely conserved through evolution. It has been characterized 
from a number of prokaryotes and eukaryotes. Nearly in all organisms, PK acts as homo-
tetramer, having 500-600 amino acids (aa) each monomer, under allosteric regulation.16 
According with its allosteric regulation, prokaryote PK is classified in type I, activated by 
fructose-1, 6-bisphosphate (FBP) and inhibited by ATP, and type II, activated by adenosine 
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monophosphate (AMP) and mono-phosphorylated sugars. Eukaryote PK is allosterically 
activated by FBP and shows cooperative activity after PEP binding. Eukaryotic PK is more 
similar to the prokaryote PK type I.17 
In human, PK is a step ahead in complexity. PK functions are carried out by four 
different isozymes, encoded by two different genes. Each of these isozymes is expressed 
under tissue specific promoters. PKM (EC: 2.7.1.40; 15q23) gene contains the sequences for 
two different isoforms, called M1 and M2. Alternative splicing of the PKM mRNA produces 
PKM1 expressed in adult tissues, such as muscle, and PKM2 expressed in rapidly 
proliferating tissues, such as fetal tissues.14 PKM isoforms are tightly regulated and PKM2 is 
important in the oncology field because an increased PKM2 expression in different 
malignancies, like breast or colon cancers, has been described.19 The other two isoforms are 
encoded by the PKLR gene. Although officially is called Pyruvate kinase, PKLR (EC: 
2.7.1.40; 1q22) is also named Pyruvate kinase 1 (to distinguish it from PKM) or Pyruvate 
kinase L/R (referring to liver/Red Cell isoforms). Similarly to what happen in PKM, 
alternative splicing of PKLR mRNAs produces LPK isoform, expressed in liver, and RPK, 
expressed in red blood cells.  
Each PK monomer presents 3 domains (Figure 2): A domain, (/)8 barrel; B domain, 
-strand inserted between 3 and 3 of domain A; and C domain, (+) open-sheet. 
Eukaryotic PK contains also an N-terminal helical domain.16  
Apart from tissue regulation, mammalian PKs show different regulation and 
kinetics. M1 is independent of allosteric modifiers and works following hyperbolic 
Michaelis-Menten kinetics. Meanwhile M2, LPK and RPK show sigmoidal kinetics, are 
allosterically activated by PEP and FBP, and inhibited by ATP.16,18 LPK and RPK are 
generated as a homotetramer (62 kDa each monomer) and afterwards two out of the four 
monomers are partially proteolyzed in its N terminus region generating smaller monomers 
(57-58 kDa). Thus, the functional tetramer is formed by combination of two complete and 
two proteolyzed monomers. This cleavage is related with cell aging and seems to be 
important for enzyme activity.20 Moreover, it has been described that LPK is also regulated 
by phosphorylation of a serine residue at the N terminus of the protein.17 
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Figure 2. Pyruvate kinase structure. 
(A, B  and  C)  PK  tetramer  from  different points  of  view:  top‐down  perspective,  90 degrees  vertically 
rotated and 90 degrees horizontally rotated, respectively. (D) PK monomer. PEP: bound to the catalytic 
site  and  FBP  bound  to  the  allosteric  activator  site.  Color  code  represents  protein  domains. Nter: N‐
terminal domain. Model based on PDB: 2VGB 18 
 
Regarding the presence of the protein on erythroid cells, must be mention that PK 
activity is carried out by both PKM2 and RPK isoforms in different proportion along 
erythroid maturation. RPK starts to take importance at basophilic stage and progressively 
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substitutes PKM2 becoming the main isozyme from orthochromatic erythroblast to mature 
erythrocytes (Figure 3).21 
 
Figure  3.  PKM2  vs  RPK  contribution  to  PK  activity  of  PKM2/RPK  isoforms  along  erythroid 
differentiation. 
 
2. PKLR, the gene 
As it has been explained, PKLR contains the genetic information for both LPK and RPK 
enzymes. Specific expression relies on the promoter regions (PKLR promoter region showed 
on Figure 4, A). It was back in 1987 when Noguchi first categorically showed that the two 
isozyme mRNAs are encoded by the same gene only differing in the 5’-terminal sequence.22 
PKLR is a 19.42 kb gene composed by 12 exons, which first two are specific for each 
isozyme (Figure  4, B). There are two accepted nomenclatures for the gene: naming the 
exons from 1 to 12, so exon 1 is erythroid and 2 hepatic; or naming from 1 to 11 for both 
isoforms, being 1(R) or 1(L) the first exon of RPK or LPK, respectively. Hereafter 
nomenclature used will be the 1-12 exons one. Erythroid exon number 1, is 14 times bigger 
than the liver homologue, number 2, which implies different protein lengths (574 aa for the 
RBC isoform and 543 aa for the liver isoform; Figure 4, C and D).23 
The expression of both isozymes depends on the regions flanking their first exon. 
On rat (81% homology between human PKLR and rat Pklr), LPK expression is controlled by 
three regions (PKL-I, PKL-II and PKL-III) and a TATA box at intron 1. Therefore the 
transcribed region occurs from exon 2 to exon 12. 24 On the other hand, first RPK transcript 
includes liver exon which is finally excluded by alternative splicing process. RPK expression 
is regulated by the region 5´upstream its first exon. Classically, a large region, from -870 to -
54 bp, has been considered important for its expression in the erythroid lineage.25 Some 
authors consider the proximal (-120 bp) region as promoter site and the distal (until -150bp) 
as enhancer sequences.26 Above all, some promoter and enhancer features have been found 
at 5’ of exon 1. More precisely, four GATA motifs (at -73, -202, -226 and -248 bp), two 
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CAC/Sp1 boxes (-107 and-119 bp) and an enhancer region (PKR-RE, -87 bp) seem to play 
important roles in erythroid expression (Figure 4, A).25,27,28  
The relevance of the proximal GATA motif has been corroborated in accordance 
with some PKD cases reported in which regions from -71 to -73 bp were mutated.29–31 
Another PKD case reported by Manco and Ribeiro showed mutations at -156 bp.32 Some 
other mutations at nucleotides -83 and -109 (PKR-RE and CAC box, respectively) 
highlighted their crucial function in RPK expression.27,33 Finally, in vitro mutations at -248 
and -324 bp turned in a non-functional RPK.27 
 
Figure 4. PKLR gene scheme, promoter, transcripts, isoforms.  
(A) PKLR promoter region including binding sequences and distances with respect to transcription start 
site (TSS). (B) PKLR gene. Exons and UTR regions are represented by boxes: red, the erythroid exon; blue, 
the liver exon; purple, exons common for both isoforms; light red, erythroid isoform 5’ UTR; light blue, 
liver  isoform 5’ UTR;  light purple, 3’ UTR common  in both  isoforms. Introns are represented as a black 
horizontal line. (C) mRNA and protein length of liver and (D) red blood cell isoforms. 
Introduction 
17 
 
 
3. Metabolic importance of PK in red blood cells 
PKLR gene is expressed in both liver and red blood cells. Therefore, mutations in 
this gene affect PK activity of hepatocytes and erythrocytes. However, the differential 
nature of these cell types means different impact of these mutations. RPK activity is the 
main source of ATP in erythrocytes while hepatocytes have nucleus and mitochondria, and 
consequently, other ways to obtain ATP such as the use of other metabolic shunts based on 
mitochondrial functions or the overexpression of LPK, something that erythrocytes cannot 
do. This is why alterations on PKLR gene produce RBC deficiency without liver affection.  
This lack of ATP production caused by mutations in PKLR gene dramatically alters 
all erythrocyte processes, affecting RBC lifespan in many ways, such as: 
Glycolysis alterations. (Figure  5) PK deficiency blocks glycolysis. PEP cannot be 
transformed in pyruvate so it is accumulated in the RBC. This metabolite regulates 
negatively the activity of Glucose-6-phosphate isomerase (GPI; which converts glucose-6-
phosphate in fructose-6-phosphate) and phosphofructokinase (PFK-1; a transferase which 
converts fructose-6-phosphate into fructose 1, 6-bisphosphate), that are the catalyzers of the 
second and the third step of glycolysis, respectively. Apart from this blocking at the 
beginning of the pathway, metabolites upstream PEP are also accumulated. Therefore, total 
amount of 2-phosphoglycerate (2-PG) and 3-phosphoglycerate (3-PG) increase. 3-PG 
activates allosterically biphosphoglycerate mutase (BPGM) which bypasses the direct 
conversion of 2-PG into 3-PG through the Rappaport-Leubering shunt. This pathway avoids 
the generation of ATP producing 2,3-biphosphoglycerate (2,3-BPG) instead, which is also 
accumulated in PK deficient RBC.34–37 
Because of the accumulation of 2,3-BPG, some authors support the idea of the 
increase of Donnan Ratio as main cause of the hemolytic anemia. In other words, changes in 
glycolysis dynamics disturb the equilibrium of charged substances across the two sides of the 
membrane. Apparently, the increase (2-3 times the normal value) of 2, 3-BPG, due to its 
polyanionic character, and the decrease of intracellular KCl reduce the normal Donnan 
ratio. These changes would explain the alterations in the PK deficient erythrocyte volume 
producing echinocytosis.38,39 
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ATP depletion. Historically, ATP depletion has been considered the main cause of 
hemolytic anemia in red cell enzymopathies.40 Normally, 90% of glucose is used to produce 
ATP trough anaerobic glycolysis.41 
 
 
Figure 5. Glycolysis and related pathways affected by a decrease of PK activity. 
(A) Metabolic pathways affected due to a decrease in PK activity. Red arrows: metabolites increased on 
PKD. Dotted red  lines: allosteric  inhibition caused by  increased metabolites. (B) Overview of metabolic 
routes affected. Green arrow: via augmented due  to PEP accumulation. Red arrows:  inhibitory effect 
increased by 2, 3 BPG increment. Red lines: Inhibited pathways due to lack of reductive power. 
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RBC do not have nuclei nor mitochondria, so decrease in PK activity causes 
impairment of the main source of energy of the erythrocyte. All the processes that require 
ATP would be affected. 
A good example is the activity of the “floppases”, that maintain the asymmetric 
distribution of lipids in the membrane in an  energy-dependent fashion42. Other affected 
functions are Na+-K+-ATPase and Ca2+-ATPase (plasma membrane Ca2+-ATPase, PMCA) that 
preserve high K+ and low Ca2+ concentrations inside RBC. Consequently, ATP deficit turns 
out in important osmotic alterations.43,44 
Additionally to the mayor features above described, lack of PK activity also affects 
other important metabolic processes in this cell type:  
Methemoglobin (mHb) increase. Apart from ATP, one of the most important 
products of glycolysis is the reduced form of nicotinamide adenine dinucleotide (NADH). 
NADH is a cofactor crucial for the activity of NADH-cytochrome b5 reductase (cytb5r), the 
main enzyme capable to reduce methemoglobin to functional hemoglobin. A deficiency in 
RPK activity decreases the source of NADH, and consequently, impairs RBC capacity to 
reduce mHb.36,45,46 
Glutathione (GSH) reduction. GSH is the main antioxidant agent present in RBC. 
The presence of GSH is necessary to avoid the toxic effect of oxidant compounds. The thiol 
groups of GSH are capable of reducing hydrogen peroxide (H2O2) to water (H2O) under the 
action of the GSH peroxidase. To be able to carry out this function, glutathione must be in 
its reduced state. GSH is reduced from glutathione disulphide (GSSG) thanks to GSH 
reductase, which requires nicotinamide adenine dinucleotide phosphate (NADPH). The 
main source of NADPH comes directly from the second step of glycolysis, where glucose-6-
phosphate enters in the  hexose monophosphate shunt (also called pentose phosphate 
pathway). Some authors point out that NADPH generation can also be disrupted by the 
increased 2,3-BPG. This compound competes with glucose-6-phosphate and 6-
phosphogluconate, substrates of two reactions of the pentose phosphate pathway, stopping 
the NADPH production.40 
Increased O2 release. Another erythrocyte function that changes because of the 
alteration of glycolysis is related with the affinity of Hb-O2 binding. It has been described 
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that the increase of organic phosphates, such as 2, 3-BPG, in RBC produces a decrease of the 
oxygen affinity. In this case, this lower affinity acts as a compensatory mechanism of the 
anemia since oxygen is more easily released to tissues.47 
As a result of all these alterations, PK deficient erythrocytes are weaker than the 
normal ones, shortening their lifespan.  
Pyruvate kinase deficiency  
1. The disease and palliative treatments 
As mentioned above, PKD is produced by mutations in the PKLR gene. PKD is 
considered a chronic hemolytic anemia. Indeed, it is the main cause of chronic non-
spherocytic hemolytic anemia (CNSHA) and hence, patients have to deal with it all over 
their lives. Despite the disease tends to stabilize during adulthood, exacerbations may occur 
due to different factors, such as pregnancy or infections.48  
There is not consensus about the prevalence of PKD, some authors estimate 5:10,000 
whereas others consider 1:20,000.48–50 In any case, both estimations are low prevalence 
values, so it is considered a rare disease. 
About a 80% of PKD patients need blood transfusions, half of them just occasional 
transfusions and the other half are transfusions dependent.51 Their Hb values vary from 11 
g/dL in mild cases to <8.5 g/dL in the most severe cases (while healthy values are 12-17 
g/dL). The most severe cases are the ones that are transfusion dependent even after 
splenectomy.35,48,49 
Another classical feature is the increased reticulocyte percentage that egress to the blood 
stream. Bone marrow tries to compensate anemia producing more erythrocytes, thus, 
reticulocyte percentage exceed the normal 2% threshold, reaching up to 30% in some severe 
PKD cases.35,49,52  
Apart from misdiagnosis of mild deficiencies or even non-diagnosed cases, there is a 
cohort of PKD cases hard to detect. These are the severe cases that affect the unborn 
patients which lately turn in intra-uterine death.48 It happens that PKD is especially 
dangerous in perinatal stages because newborns are not able to compensate anemia. Hence, 
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PKD is associated with hydrops fetalis, a generalized edema that presents with cardiac 
failure, threatening fetus´s life.53 
Furthermore, the direct consequence of hemolytic anemia after birth is neonatal 
jaundice. This condition is present in 30-50% of the cases if the anemia is mild or moderate 
and up to 90% if it is severe. Treatment varies from phototherapy (93% of the cases) to 
exchange transfusion (46% of the cases) depending on severity.48,51  
As it has been explained before, PKD erythrocytes are fragile and tend to suffer 
hemolysis. Similarly as described in other hemolytic anemias, PKD produces increase in 
bilirubin level, a sub-product of Hb metabolism, and decrease haptoglobin level, the protein 
which binds free Hb to avoid its oxidative action.50 
 Equally important is the loss of RBC that are retained and eliminated in the spleen. In 
normal conditions, spleen is the agent which removes senescent RBC from the circulation. 
Since PKD erythrocytes are impaired spleen detects them as abnormal and destroys them. 
Consequently, spleen´s overwork increases organ´s size producing splenomegaly. Besides, 
spleen eliminates reticulocytes too, which partially counteracts the compensation that bone 
marrow develops.54,55 Thus, splenectomy is carried out as palliative treatment for PKD. This 
strategy is meant to avoid RBC destruction, either reticulocytes or abnormal erythrocytes, 
increasing the global number of cells transporting oxygen. Splenectomy does not arrest 
hemolysis but results in an increase of Hb values around 1-3 g/dL and reduce or abolish the 
transfusion requirement in most cases. Moreover, it also increases reticulocyte percentage 
reaching 70% in some patients.35,48,49 However, this medical practice implies several 
complications, such as risk of sepsis because of defective defense against encapsulated 
organisms, thromboembolic disease (that affects 11% of splenectomized patients)51, injury to 
the tail of the pancreas, hepatic or portal vein thrombosis, among others.5,48 
One of the collateral problems of these two palliative treatments is iron overload. In few 
cases, PKD patients show special susceptibility to iron overload caused by mutations in iron 
metabolism.56,57 Apart from these, blood transfusion is principal actor involved in iron 
overload, affecting 48% of splenectomized patients.51 Serum ferritin values rise after each 
transfusion and the lack of spleen impairs the recycling capacity of iron species. This 
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condition requires appropriate medical control, for instance, based on the use of iron 
chelation. Otherwise, it can be life-threatening.48,58,59  
There are some others frequent clinical manifestations such as gallstones (that appear in 
45% of splenectomized patients and 48% of which require cholecystectomy)51, leg ulcers, 
splenic abscess, kernicterus or acute pancreatitis, all of them related with alterations of iron 
and hemoglobin metabolism.31,45,58,60,61 
Recently, it has been published another possible approach to minimize PKD. AG-348 is 
a PK allosteric activator that is able of increasing the enzymatic activity even in some 
mutated PKs, so it has been proposed as possible treatment. 62 A phase II clinical trial started 
in 2015 in which 25 patients were treated ≥3 weeks with AG-348. After treatment, 13 PKD 
patients (52%) showed hemoglobin (Hb) increase >1.0 g/dL. Differential responses were 
probably due to variability on mutations since AG-348 depends on mutated PK structure to 
work.63  
2. PKLR mutations 
PKD is an autosomal recessive disorder and most patients are compound heterozygous. 
Up to 256 variants of PKLR gene have been sequenced, among which only 6 are 
polymorphisms that do not affect the protein sequence (Figure 6, A). Among exonic 
mutations, single substitution is the most common type of mutation, 72% (67% missense 
and 5% nonsense), while deletion, insertion or deletion plus insertion are minority (9%, 3% 
and 1%, respectively). 50 
Apart from mutations in exons, it is demonstrated that PKD can be produced because of 
alterations in promoter regions, such as GATA-1 binding site, or because of changes of 
splicing sites within intron regions.50  
In general, mutations are spread all over the gene being more frequent between exons 7 
and 11 (Figure 6, B). Some mutations are more reported in a geographic region than others. 
For instance, 1529G>A is the most common mutation in north Europe and USA (42%), 
1456C>T in south Europe (41%) and 1468C>T in Asia (29%).35,48 
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Figure 6. Reported mutations along PKLR gene and RPK protein.  
(A) Mutations  causing  PKD  reported  all  over  exons  (top)  and  introns  (bottom),  including  promoter 
region. Red:  single nucleotide  substitution; purple: deletions; orange:  insertions; blue: deletions plus 
insertions;  green:  SNPs  that  do  not  affect  the  protein  sequence.  Numbers  inside  the  bars  are  the 
amount of different variants found. (B) PK monomer showing, in red, PKD mutations described. Yellow, 
orange and blue are the most represented mutations  in different geographic regions. Model based on 
PDB: 2VGB 18 
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The official reports claim that more than 80% reported cases are placed in Europe and 
Asia (61% Europe, 22% Asia). But probably it doesn’t represent the real distribution of the 
disease because it barely includes data from Latin American or African territories. It is also 
known that PKD confers protection against malaria; consequently, a higher incidence would 
be expected in places where malaria is present. Africa, for instance, represents less than 5% 
of the mutations described.48,64,65 
Finally, some ethnic minorities present an abnormally high mutation frequency. This 
phenomenon is justified by founder effect and endogamy. These are the cases of the Ohio 
and Pennsylvania Amish (1436G>A) and the gipsy communities (deletion of exon 11).50,66,67 
3. Diagnosis  
Some of the symptoms described in the previous section can be useful to diagnose PKD. 
Reticulocytosis, splenomegaly, increased bilirubin, are normal features among hemolytic 
anemias, so the difficulty lies in distinguishing PKD from other hemolytic anemias. 
Classically, PKD has been related with the presence of spiculated erythrocytes. This 
phenomenon, named echinocyte, correlates with a decrease of K+ level as described for 
PKD.5 Nevertheless, it cannot be used as a differentiating factor because in numerous PKD 
cases erythrocytes have shown normal shape.35 Furthermore, echinocytes are also present in 
other anemias and disorders, such as renal failure.5 
Thus, the unique biochemical marker characteristic of PKD is the decrease in PK 
activity. Normally, it is expressed in UI/gHb but it can be found as pyruvate kinase 
activity/hexokinase activity ratio (PK/HK). Reticulocytes have higher PK activity than 
erythrocytes. Hence, to make PK activity reliable, this augmented activity in reticulocytes is 
normalized by HK, which also decreases during RBC maturation. PK/HK ratios between 
7.2-15.6 are considered normal. Values under this threshold can be considered PK 
deficiency markers. 
Regarding PK activity evaluation, some authors have suggested that PKD can be 
compensated for a persistent presence of PKM2 in mature erythrocytes.68,69 On the other 
hand, most authors claim that PKM2 activity cannot be detected in mature PKD 
erythrocytes. Furthermore, it seems that PKM2 activity detected in some cases must be due 
to an incomplete removal of leucocytes during purification.48,50,70 
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Although the diagnosis of PK deficiency is based on the demonstration of a reduced PK 
activity, the final diagnosis must be based on a complete genetic sequencing of PKLR. 
Normally, the study is also performed in the parents in order to trace the origin of the 
mutations.  
After diagnosis, disease is classified based on its severity. The guides for this 
classification are hemoglobin level, frequency of blood transfusions and the need of 
splenectomy. Also, the improvement of these parameters after splenectomy is taken into 
account. Normally, patients are divided in 3 groups: mild, moderate and severe. Sometimes a 
fourth group, very severe, is included, for those who are transfusion-dependent even after 
splenectomy (Table 1).48,49 
Table 1. Patient classification based on the severity of their phenotype. 
    I. Mild  II. Moderate  III. Severe  IV. Very Severe 
Neonatal 
features 
Jaundice  30‐50% cases  30‐50% cases  90% cases  90% cases 
Transfusions  Rare  Rare  Always  Always 
           
    I. Mild  II. Moderate  III. Severe  IV. Very Severe 
Adult 
features 
Splenectomy  Rare  Sometimes  Always  Always 
         
Pre‐ splenectomy 
Hb (g/dL)  >10  8‐10  <8  <8 
Transfusions  Rare  Common  Periodic  Periodic 
         
Post‐ splenectomy 
Hb (g/dL)    10  ≥8  <8 
Transfusions    Only exacerbations  Only exacerbations  Periodic 
 
Interestingly, genotype/phenotype association is not clear. Sometimes specific mutations 
have been associated with a tendency to produce concrete phenotypes (e.g. homozygous for 
1456C>T tends to produce mild PKD cases).48 But the study of 27 patients homozygous for 
the same mutation (1529G>A) showed that multiple outcomes are possible having the same 
genetic profile. Among these 27 patients, Hb values vary between 4.9 and 12.2 g/dL and 
their reticulocyte percentage from 4 to 66 %.35 However, other authors have reported a 
worse prognosis in the case of patient with double non-missense mutations (including 
nonsense, in frame small insertion/deletion, large deletions and mutations in splicing sites) 
compared with double missense (M/M) or compound missense/non-missense (M/NM) 
genotype.35,51 
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Curative treatments for PKD 
1. Hematopoietic allogeneic stem cell transplantation 
As others hematopoietic genetic diseases, the only way to completely cure PKD is to 
reproduce a healthy hematopoiesis. Up to the date, the unique curative treatment carried 
out in humans is hematopoietic allogeneic stem cell transplantation (HSCT). Until 2017, 
only 4 cases of curative outcome had been reported despite of the fact that there were more 
PKD patients transplanted.59,71,72 A recent study has collected information of a total of 16 
PKD transplanted patients. The life-threatening drawbacks of HSCT for PKD patients are 
the common in this kind of transplant: graft versus host disease (GVHD) and infections. 
Survival rate after a 3 year follow-up was 65% (7/16 have not reach 3 years milestone yet). 
Transplant outcome was clearly better in the case of patients younger than 10 years old 
(90%).73 This value is lower compared to the survival percentage of most HSCT for different 
alterations, such as malignancies or autoimmune diseases (73-93%)74 but higher than in 
HSCT for other anemias.75 
One of the most harmful complications, GVHD, appeared in 38% PKD patients. In this 
case, it is higher than in other allogenic transplant for other inherited hematopoietic 
diseases, such as Fanconi anemia (<19%), but lower than Diamond Blackfan anemia 
(57%).74–76 
This important drawback of HSCT, caused by haplotype discrepancies, resulting in 
immune responses that threat the treatment success could be overcome by means of 
transplant of genetically corrected autologous hematopoietic progenitors. 
2. Gene therapy, addition strategy 
Monogenic diseases, like PKD, are the perfect scenario for gene therapy. In this kind of 
diseases, the most common strategy consists in the addition of functional copies of the gene 
that is mutated in the patients. Corrected patient cells are able to recover the 
protein/function that causes the disease. There are multiple ways to deliver the DNA into 
patient cells, among which the use of viral vectors is the most common. Numerous gene 
therapy clinical trials based on this approach have been performed and are still ongoing.77 
Gene therapy for PKD has not reached that point yet.  
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Some pre-clinical trials have been carried out showing the feasibility of gene therapy in 
PKD. Back in the 90´s, hematopoietic progenitor cells from healthy C57BL/6 mice were 
transduced with a retroviral vector containing the coding DNA of the human PKLR and 
transplanted into lethally irradiated C57BL/6. PKLR mRNA was detectable in recipient bone 
marrow until 135 days post-transplant.78 In our previous work, published in 2009, we used a 
PKD mouse model (AcB55) to demonstrate the phenotypic rescue after gene therapy. In this 
case, the vector used was a -retrovirus backbone containing the spleen focus-forming virus 
(SFFV) promoter and the human RPK cDNA. Correction of 25% bone marrow cells was 
sufficient to rescue the animals from the main clinical features.79 
In 2012, another PKD animal model was used to test the feasibility of gene therapy to 
treat PKD. It was a Basenji dog, a race in which this disease is relatively common. PKD in 
dogs is pretty similar to the human deficiency, being life-threatening in some cases. This 
dog, tagged H145, was treated by gene therapy using a foamy viral vector. To drive the 
transgene expression, PGK promoter (phosphoglycerate kinase promoter) was chosen. PGK 
promoter provides a high constitutive expression and it is commonly used in gene therapy. 
In this case, the transgene was the canine RPK. As happened in the mouse model, the 
therapy cured the dog, making it transfusion-independent.80 
However, gene therapy scenario changed after the report of insertional oncogenesis 
cases produced by -retroviral vectors. It turned out that -retroviral vectors tend to 
integrate near proto-oncogenes, such as cell cycle regulatory genes, with dramatic 
consequences.81–86  
A long way towards safe gene therapy has been walked. Many efforts have been focused 
on developing safe and efficient viral vectors. Among the new vectors used, self-inactivating 
lentiviral vectors have shown good transduction levels and there are no reported cases of 
insertional mutagenesis in any of the more than 150 opened clinical trials so far.87 
Recently, our group has shown PKD correction using a lentiviral-based gene therapy. 
The construct uses an internal PGK promoter to express a codon optimized version of 
human RPK cDNA. PKD mice (AcB55) recovered a healthy phenotype after the transplant 
of corrected hematopoietic progenitors containing about 1 viral copy per cell.87 The success 
of these pre-clinical trials allowed us to apply for orphan drug designation, obtaining it from 
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EMA (European Medicines Agency) and from FDA (Food and Drug Administration) in 2014 
and 2016, respectively. A clinical trial is planned to be opened on 2019 to test the developed 
medical product. Before this, some additional information is required. For example, what 
minimum viral copy number of therapeutic vector is required to restore a healthy 
phenotype is fundamental to decide the transduction efficacy required for a therapeutic 
treatment. 
3. Gene editing approaches 
One of the characteristics of addition gene therapy is that the abnormal protein is not 
removed and coexist whit the corrected one. However, sometimes this fact can impair the 
efficacy of the therapy due to competition between the endogenous and the transgene 
protein. Moreover, addition gene therapy does not reproduce the natural regulation of the 
expression of the gene introduced.  
Our group has also been working in a gene editing-based approach to correct PKD. 
Induced pluripotent cells (iPSCs) derived from PKD patient cells were corrected by 
homologous recombination. In this process, genomic DNA was cut at intron 2 thanks to the 
activity of specific TALEN. A DNA matrix containing an optimized version of PKLR gene 
was introduced by homologous recombination. After recombination, codon optimized 
sequence was located after endogenous 2nd intron, therefore, the new chimeric gene 
expression remained under the original promoter regions. This strategy permitted the 
transgene expression under the endogenous tissue specific signals and also interrupted the 
expression of the deficient copy of PKLR gene, avoiding isoform competition. Cells were 
amplified in vitro and their energetic deficit due to PKD was corrected.88 
PKD models and gene editing tools 
1. PKD animal models 
As it has been briefly commented above, several animal species that suffer pyruvate 
kinase deficiency have been used as models to study the disease.  
Different mutations have been described in canine PKLR gene. Some affected dog 
breeds, such as West Highland white terrier89–92 and Cairn terrier93, present a 6 bp insertion 
in exon 10 that produce deficiency on RPK. Other mutations have been found in different 
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breeds: in Beagle (missense mutation, c.994G>A, exon 8)91,93, in Labrador retriever 
(truncating mutation, c.799C>T, exon 7)93, in Pug (missense mutation, c.848T>C, exon 7)93 
and a deletion of a C (c.433delC) in Basenji dog.80,94–96 Among these dog breeds, only Basenji 
dogs have been used as PKD model for innovative therapies as it has been described in 
previous section.80 
PKD has been also shown in domestic cats. Although it is less studied at genetic level, it 
is stablished that this condition affects different cat breeds, especially in Abyssinian and 
Somali cats.97 Nevertheless, a study on different cat strains (Bengals, Egyptian Maus, La 
Perms, Maine Coon cats, Norwegian Forest cats, Savannahs, Siberians, Singapuras, 
Abyssinians and Somalis) indicated that a polymorphism (c.693+304G>A) shared by PKD 
cats among all this types could be maybe the cause of the disease.98 Although feline PKD 
model is normally considered in veterinary field, it has not been used to test any innovative 
therapies such as gene therapy. 
Regarding mouse models, it was back in 1995 when Masahiro Morimoto and 
collaborators realized that an inbred colony of CBA/N mice that they had in SLC Haruno 
farm (Shuchi-gun, Shizuoka, Japan) presented splenomegaly and nonspherocytic hemolytic 
anemia. Also, a marked reticulocytosis was also observed (41.6%) compared with healthy 
CBA/N (2.8%). These features were due to a homozygous mutation in exon 8 of Pklr gene 
(1013 G>A). They called this strain CBA-Pk-1slc/Pk-1slc. Pk-1 was the old name for Pklr gene 
and slc named the farm where they found the mutated strain. This missense mutation 
produced a change at PEP binding site (338 Gly>Asp) reducing 90% PK activity. This model 
was used to demonstrate the feasibility of bone marrow transplantation to correct PKD. 99,100  
The other mouse model, the mentioned AcB55, was found during a screening to find 
susceptibilities against malaria.101 It was the inbreeding of a malaria-susceptible strain (A/J) 
and a resistant one (C57BL/6J) what generated a new strain with a mixed genetic 
background (approximately 87.5% and 12.5%, respectively). These new malaria resistant 
mice had a mutation in exon 2 (269T>A) of Pklr gene that induced an Ile90Asn substitution. 
AcB55 mice present reticulocytosis and splenomegaly due to the PKD chronic anemia and 
have been used as model in this work.65,102 
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Despite having several animal models available, there is not a PKD model based on 
human cells. Moreover, the normal follow-up of the patients does not include bone marrow 
aspirations so hematopoietic progenitors collection to study the disease is quite limited.  
2. Strategies to generate human disease model in human cells 
Classically, drugs, such as enzymatic antagonists, have been used to reproduce protein 
impairment in vitro to generate disease models. But the effect stops once the drug is not 
present. To obtain a more stable human PKD model, two approaches can be followed, 
decreasing mRNA level of the gene of interest or directly modifying the gene thereby 
avoiding even the mRNA release.  
2.1 Short hairpin RNAs	
A first approach to generate stable disease-like cells is the use of lentiviral vectors 
containing short hairpin RNAs (shRNAs) to knock down the desired mRNA. These small 
RNAs are compound for two self-complementary sequences separated by a few nucleotides 
that form a loop. These sequences are also specific to the mRNA of interest. After being 
synthetized in the nucleus, pre-shRNAs are processed and transported to the cytoplasm. 
Once in the cytoplasm, Dicer enzyme with Tat–RNA-binding protein (TRBP) and PACT 
(PKR activating protein) process the loop of the hairpin to transform them into mature 
double-stranded siRNAs with 2 nucleotides 3´ overhangs. These mature siRNAs are then 
ready to act, associated with the RNA-interfering silencing complex (RISC) scan the mRNA 
of interest and eliminate it.103,104  
This strategy has been extensively used in vitro in cell lines for basic research105,106, in 
vivo in different animal models107–109 and also to generate human disease-like cells110,111. A 
similar strategy could be used to generate PKD-like human progenitors. 
2.2 Gene editing using nucleases	
Other strategy used to generate gene deficient cells is the application of the recently 
developed gene editing tools to induce DNA breaks in the target gene. After these breaks, 
endogenous cell machinery repair them by non-homologous end joining, an error-prone 
mechanism that alters the original sequence resulting in gene disruption. Several nucleases 
have been developed and used to generate these DNA breaks, such as homing endonucleases 
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(meganucleases), zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases 
(TALENs), and clustered regularly interspaced short palindromic repeats (CRISPR) together 
with Cas (CRISPR associated) nuclease.112–115 Among all of them, the latter one has 
demonstrated being the most versatile. For this, CRISPR/Cas9 technology was the selected 
one to modify permanently healthy hematopoietic progenitors in this thesis to generate 
human PKD-like cells. 
CRISPR/Cas is part of the adaptive immune system of prokaryotes against viral hazard. 
Despite of the fact that the number of proteins that form the CRISPR differs among 
organisms, all of them share the same goal, the elimination of viral DNA to stop their 
invasion. In nature, CRISPR are formed by arrays of small sequences complementary to viral 
DNA spaced by repeated motifs. After the processing of these small RNAs, they are ready to 
scan these specific viral sequences and link to them. Cas nucleases, associated to this 
immune system, are joined to these complexes formed by CRISPR RNA and viral sequences 
and cleave them, protecting the prokaryotic organism from the viral actions.116–119 
Normally, the CRISPR/Cas systems used in molecular biology are the simplest ones, for 
instance those in which nuclease activity is carried out by a single nuclease instead of a 
protein complex (Figure 7). 
Originally, it was composed by three separated elements: the so called crRNA, CRISPR-
spacer array that contained specific sequences (about 20 bp-long each) complementary to 
viral DNA; tracrRNA (trans-activating crRNA), an element that joins to the crRNA and acts 
as scaffold for the nuclease union; and the Cas 9 nuclease, which joins to tracrRNA and to 
the DNA motifs called PAM (protospacer adjacent motif), 5’-NGG-3’ in the case of S. 
pyogenes.120 For the gene editing approach used in this thesis to generate human PKD-like 
cells, crRNA sequences used were specific for the interest gene and crRNA and tracrRNA 
were used in the artificial linked form as a single sequence called single guide RNA or just 
gRNA.122 Thus, gRNA forms a heteroduplex with the specific DNA sequence and the two 
catalytic domains of Cas9 (RuvC and HNH), generating a double strand break (DSB) 
between the 3rd and 4th nucleotide at 5’ of the PAM region.116,117,120 
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Figure 7 . Streptococcus pyogenes Cas9 structure joined to gRNA and targeted DNA. 
(A)  Cas9  protein  surrounding  target DNA.  Yellow  strand:  targeted DNA;  light  blue  strand:  guideRNA 
complementary to targeted sequence; dark red circle: HNH nuclease domain location, this domain is not 
shown  to visualize DNA heteroduplex;  light blue domain: RuvC nuclease domain; small purple  region: 
PAM.  (B) PAM nucleotides  joined  to Cas 9´s  arginine  residues. DNA  and  gRNA union  represented by 
sequence  (C) and by 3D  structure  (D). C and D  schemes  show gRNA generated by  joining  crRNA and 
tracrRNA. Figures modified from 120,121. 
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Chronic hemolytic anemias, such as PKD, alter normal hematopoiesis increasing the 
egress of immature erythrocytes, being reticulocytosis and splenomegaly some of its main 
features. The general aim of this work was to reach a better understanding of the anemic 
processes that happen in PKD patients through a complete analysis of their peripheral 
blood. Also, to find out if the compensatory mechanisms carried out by bone marrow affect 
other cell types such as erythroid progenitors and hematopoietic stem cells, as well as 
immune cells. Expand our knowledge studying patient samples would help us to understand 
the disease and would approach us to the eventual clinical trial. To make this clinical trial 
possible, beyond knowing the disease itself, it is also necessary to know the behavior of the 
disease when is challenged by gene therapy. The therapeutic vector previously developed by 
our lab (named coRPK in this thesis) demonstrated its efficacy to cure PKD in an animal 
model and was designated orphan drug by the EMA and FDA. An evaluation of the 
performance of the viral vector in limiting situations, to define the scenario in which 
clinical trial would be conducted is needed. Ideally this experiment should be carried out in 
human cells, but the source of PKD hematopoietic progenitors to test this and other 
approaches is limited to the few thousands of hematopoietic stem cells present in the 
peripheral blood samples. To beat this limitation, it is necessary to generate human PKD-
like cells out of healthy CD34+ cells. 
For all these reasons, the specific objectives of this thesis were: 
1. To further study the extent of hematopoietic alterations in PKD patient samples. 
2. To find out if anemic situation affects more primitive populations than reticulocytes. 
3. To define the minimum number of corrected cells capable to rescue PKD mice from 
the deficient phenotype. 
4. To generate PKD-like cells from healthy hematopoietic progenitors using two 
different strategies: mRNA knock-down by short hairpin RNAs and genome editing 
by CRISPR/Cas9 system.  
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Primary cells sampling 
1. Human hematopoietic progenitors (CD34+) 
Hematopoietic CD34+ progenitors were obtained from cord blood (provided by 
Centro de Transfusión de Madrid) or from peripheral blood (provided by associated 
physicians) based on the following process. First, total blood was separated by density 
gradient using Ficoll-Paque PLUS (GE healthcare) according to manufacturer´s instructions. 
Then, mono-nucleated cell layer was collected and washed with PBE (Dulbecco’s Phosphate 
Buffered Saline, Sigma, herein after named PBS; HyClone 2%, GE Healthcare; EDTA 2 
mM). After counting the cellularity, CD34+ cells were labeled with anti-CD34 antibody 
joined to magnetic beads using CD34 MicroBead Kit (Miltenyi Biotec) and purified by 
positive selection using two columns, named LS and MS (Miltenyi Biotech), sequentially 
(attached to QuadroMACS separator and OctoMACS separator magnetic supports, 
respectively, Miltenyi Biotech). CD34+ cell enrichment achieved, analyzed by flow 
cytometry, was always above 90%. 
In the case of PKD peripheral blood samples, mono-nucleated cells were also 
isolated using Ficoll-Paque PLUS (GE healthcare) but no CD34+ purification step was 
performed. 
Human blood cell counts were measured on a COULTER Ac•T cell counter 
(Beckman Coulter). 
2. Mouse hematopoietic progenitor sampling 
A mouse hematopoietic progenitor cell population, hereafter named Lin-, was used 
in this thesis. The name corresponds to its immunophenotype since they are negative for all 
hematopoietic mature lineages including erythroid (Ter119), T lymphocytes (CD3), mature 
B, T lymphocytes and monocytes (CD45R), myeloid and NK cells (CD11b) and granulocytes 
(GR1). 
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Total bone marrow cells (obtained from femur and tibia) were treated with 
ammonium chloride buffer (NH4Cl 0.155 M, KHCO3 0.01 M, EDTA 0.1 mM; 10 minutes of 
incubation at room temperature) to eliminate mature red blood cells fraction. Cells were 
washed with PBS, suspended in the same buffer (109 cells/mL), incubated with the antibody 
cocktail gathered on Table 2 for 30 minutes at 4ºC, washed again with PBS containing 2% 
bovine serum albumin (BSA, Sigma) and 2% penicillin/streptomycin (Gibco) and purified by 
fluorescence activated cell sorting using an Influx™ cell sorter (BD).  
Table 2. Flow cytometry antibodies used to purify mouse hematopoietic progenitors. 
  Epitope  Fluorochrome  Clone  Provider  Catalogue #  Vab/100µL (µL) 
Lin‐ 
Ter119  PE  TER119  BD Pharmigen  553673  0.1 
CD45R (B220)  PE  RA3‐6B2  BD Pharmigen  553090  0.2 
CD3  PE  145‐2C11  BD Pharmigen  553064  0.2 
CD11b  PE  M1/70  BD Pharmigen  553311  0.2 
GR1  PE  RB6‐8C5  BD Pharmigen  553128  0.2 
 
3. Mouse peripheral blood sampling 
Peripheral blood samples were taken from the tail vein and collected on EDTA 
coated tubes (Microvette CB 300 K2E, Sarsted). Complete blood count was measured using 
an abacus Junior Vet (Diatron). 
Experimental animals 
PKD mouse model used in this thesis was the recombinant congenic mouse AcB55 
(Emerillon Therapeutics Inc., Montreal, Quebec, Canada) which genetic background was 
12.5% of A/J and 87.5% C57BL/6 (B6). Healthy wild type C57BL/6 (B6) and A/J mice were 
used as controls. All, PKD and control mice were maintained at the Laboratory Animal 
Facility of CIEMAT (28079-21A) by inbreeding. 
Mice were maintained under standard diet (water and food ad libitum) and all 
protocols were done following the European and Spanish laws and regulations (ETS123 
European convention about the use and protection of vertebrate mammals used in 
experimentation and other scientific purposes and Spanish law RD 53/2013). 
Materials and Methods 
 
43 
 
Primary cell cultures 
1. Human hematopoietic progenitor medium 
Human hematopoietic progenitors were cultured in StemSpan SFEM I (Stem Cell 
Technologies) supplemented with human stem cell factor (hSCF, 100 ng/mL; 
EuroBioSciences), recombinant human thrombopoeitin (hTPO, 100 ng/mL; 
EuroBioSciences), human FMS-like tyrosine kinase 3 ligand (hFlt3-ligand, 100 ng/mL; 
EuroBioSciences), Glutamax (1%; Gibco), penicillin/streptomycin (1%; Gibco). Cells were 
maintained at 1x106 cell/mL concentration. Incubation conditions were the following: 37ºC, 
5% CO2 and 95% relative humidity.  
2. Erythroid differentiation protocol 
 
Human hematopoietic progenitors were differentiated toward erythroid lineage 
using 4 different media (Figure 8). The first medium, days 1 to 7, was based on StemSpan 
SFEM I (Stem Cell Technologies) supplemented with hSCF (50 ng/mL; EuroBioSciences), 
hFlt3-ligand (16.7 ng/mL; EuroBioSciences), bone morphogenetic protein 4 (BMP-4, 6.7 
ng/mL; Peprotech), human interleukin 3 (hIL-3, 6.7 ng/mL; EuroBioSciences), human 
interleukin 11 (hIL-11, 6.7 ng/mL; EuroBioSciences) and human erythropoietin (h-EPO, 1.3 
U/mL; Amgen).  
 
Figure 8. Erythroid differentiation protocol. 
 
Cells were then transferred to the second medium in which they were culture on 
days 7 to 14. Second medium was based on Iscove’s modified Dulbecco’s medium Glutamine 
supplemented (IMDM GlutaMAX supplemented; Gibco) enriched with BSA (1%; Sigma), 
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insulin (0.01 mg/mL; Sigma), human transferrin (0.2 mg/mL; Sigma), -mercaptoethanol (91 
µM; Gibco), penicillin/streptomycin (1%; Gibco), lipid mixture 1 (1x; Sigma), ethanolamine 
(0.004%, Sigma), hSCF (5 ng/mL; EuroBioSciences), hIL-3 (6.7 ng/mL; EuroBioSciences), 
hIL-11 (6.7 ng/mL; EuroBioSciences), hEPO (1.3 U/mL; Amgen), insulin-like growth factor-
1 (IGF-1, 20ng/mL; PeproTech) and hydrocortisone (1 µM; Sigma).  
After day 14 and for 2 days, cells were transferred to the third medium that was also 
based on IMDM GlutaMAX medium (Gibco) supplemented with BSA (1%; Sigma), insulin 
(0.01 mg/mL; Sigma), human transferrin (0.2 mg/mL; Sigma), -mercaptoethanol (91 µM; 
Gibco), penicillin/streptomycin (1%; Gibco), lipid mixture 1 (1x; Sigma), ethanolamine 
(0.004%; Sigma) and hEPO (10 U/mL; Amgen). 
Final enucleation was carried out for five days on the forth medium that was also 
based on IMDM GlutaMAX medium (Gibco) supplemented with BSA (1%; Sigma), insulin 
(0.01 mg/mL; Sigma), human transferrin (0.2 mg/mL; Sigma), -mercaptoethanol (91 µM; 
Gibco), penicillin/streptomycin (1%; Gibco), lipid mixture 1 (1x; Sigma) and ethanolamine 
(0.004%; Sigma). 
All media were filtered by 0.22 µm before use. Sampling and analysis were done 
within this third week. During erythroid differentiation, cells were maintained between 
4x105 and 4x106 cell/mL concentration. Incubation conditions were also 37ºC, 5% CO2 and 
95% relative humidity. 
3. Mouse hematopoietic progenitor medium 
Mouse hematopoietic progenitors (Lin-) were maintained on StemSpan SFEM I 
(Stem Cell Technologies) supplemented with mSCF (50 ng/mL; EuroBioSciences), hTPO (20 
ng/mL; EuroBioSciences), hFlt3-ligand (25 ng/mL; EuroBioSciences), hIL-3 (10 ng/mL; 
EuroBioSciences), hIL-6 (10 ng/mL; EuroBioSciences) and penicillin/streptomycin (1%; 
Gibco). Cells were maintained at 106 cell/mL. Incubation conditions were the following: 
37ºC, 5% CO2 and 95% relative humidity. 
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Colony forming unit assay 
1. Human hematopoietic progenitors 
The presence of hematopoietic progenitors on PKD patient peripheral blood was 
evaluated according with the following protocol. Mononuclear hematopoietic cells were 
cultured on methyl cellulose (StemMACS™ HSC-CFU completed with EPO; Miltenyi) at 
250,000 cells/mL concentration. Triplicates were performed for each sample using 1 mL for 
each replica. After 14 days of incubation (37ºC, 5% CO2, 95% relative humidity), colonies 
were scored using an inverse phase contrast Nikon ELWD 0.3 microscope. 
2. Mouse hematopoietic progenitors 
Purified hematopoietic progenitors were cultured on methyl cellulose (Methocult 
GF M3534; Stemcell) at 1500 cells/mL concentration. Triplicates were performed for each 
sample using 1 mL for each replica. After 7 days of incubation (37ºC, 5% CO2, 95% relative 
humidity), colonies were scored using an inverse phase contrast Nikon ELWD 0.3 
microscope. 
Cell line cultures 
  K562 cell line (chronic myelogenous leukemia; ATCC: CCL-243) was cultured in 
Iscove’s modified Dulbecco’s medium (IMDM; Gibco), HyClone (10%; GE Healthcare) and 
penicillin/streptomycin (1%; Gibco). Cells were maintained at 1x105-1x106 cell/mL. 
HT1080 cell line (fibrosarcoma cell line; ATCC: CCL-121) was cultured in 
Dulbecco’s modified Eagle´s medium (DMEM; Gibco), HyClone (10%; GE Healthcare) and 
penicillin/streptomycin (1%; Gibco). Cells were maintained at 1x105 cell/mL. 
HL60 cell line (promyeloblast cell line; ATCC: CCL-240) was cultured in Iscove’s 
modified Dulbecco’s medium (IMDM; Gibco), HyClone (10%; GE Healthcare) and 
penicillin/streptomycin (1%; Gibco). Cells were maintained at 1x105-1x106 cell/mL.  
Lymphoblastic cell line (LCL, generated from B cells from healthy donor and kindly 
provided by Dr. Paula Río, CIEMAT) was cultured in Roswell park memorial institute 
medium (RPMI; Invitrogen), HyClone (20%; GE Healthcare), penicillin/streptomycin (1%; 
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Gibco), -mercaptoethanol (5 µM; Gibco), sodium pyruvate (1mM; Sigma) and non-essential 
aminoacids (1x; Lonza). Cells were maintained at 1x105-1x106 cell/mL.  
HEK293T cell line (human embryonic kidney cell line competent to replicate 
vectors carrying the SV40 T antigen; ATCC: CRL-3219) was cultured in Iscove’s modified 
Dulbecco’s medium (IMDM; Gibco), HyClone (10%; GE Healthcare) and 
penicillin/streptomycin (1%; Gibco). Cells were maintained at 5x105 cell/mL concentration.  
Incubation conditions were the same for all cell lines used: 37ºC, 5% CO2 and 95% 
relative humidity. 
Flow cytometry 
1. PKD patients characterization 
Immunophenotype of PKD patient and healthy donor samples were analyzed by 
flow cytometry using five different panels specified on Table 3. For panel 1, that 
corresponds to the reticulocyte study, 5 µL of non-lysed peripheral blood samples were 
added to 2 mL of PBS plus acridin orange at specified concentration. After 10-30 minutes of 
incubation, lectures were done not later than 1 hour after acridin orange addition. For the 
rest of the panels, antibodies were added at concentrations showed in the table, incubated 
for 30 minutes at 4ºC and then washed with PBA (PBS with 0.2% sodium azide [Merck]; 1% 
BSA [Sigma]). For panel 1 and 2, peripheral blood samples were pre-diluted in PBA at 1:400 
and 1:10 ratios, respectively. After antibody incubation, a lysis step with ammonium 
chloride buffer was performed to panels 3, 4 and 5 to remove erythrocytes. DAPI (4', 6-
diamidino-2-phenylindole) at final concentration of 1 µg/ml were added to identify dead 
cells. Events were acquired and recorded with a LSR Fortessa (BD Biosciences) and flow 
cytometry data were analyzed by FlowJo software (BD Biosciences). 
Table 3. Flow cytometry antibodies used to characterize PKD patient. 
Panel  Reagent  Provider  Catalogue # 
Vfinal 
(mL)  Concentration 
1  Acridin Orange  Molecular Probes  A3568  2  0.025 µg/ml 
Panel  Epitope  Fluorochrome  Clone  Provider  Catalogue # 
Vfinal 
(µL)  Vab/Vfinal 
2  CD71  PE  YDJ.1.2.2  Beckman Coulter  IM2001U  50  0.04 
CD235a  FITC  11E4B‐7‐6  Beckman Coulter  B49206  0.10 
3 
CD34  PE  8G12  BD Pharimigen  345802 
100 
0.05 
CD38  FITC  T16  Immunotech  IM0775  0.05 
CD45  APC  2D1  Biolegend  368512  0.10 
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4 
CD3  APC  UCHT1  BioLegend  300439 
100 
0.04 
CD4  PE  13B8.2  Beckman Coulter  A07751  0.04 
CD8  FITC  B9.11  Beckman Coulter  A07756  0.04 
CD45  APCCy7  HI30  BioLegend  304014  0.03 
5 
CD3  APC  UCHT1  BioLegend  300439 
100 
0.04 
CD14  BV711  M5E2  Biolegend  301837  0.02 
CD15  PE  VIMC6  Miltenyi Biotec  130‐091‐375  0.04 
CD19  PECy7  SL25C1  eBioscience  25‐0198‐42  0.03 
CD45  FITC  J33  Beckman Coulter  A07782  0.06 
 
2. Erythroid differentiation immunophenotype 
Immunophenotype of hematopoietic progenitors differentiated toward erythroid 
lineage was analyzed by flow cytometry using the antibody combination specified on Table 
4. 
Table 4. Flow cytometry antibodies used to follow in vitro differentiation along erythroid lineage. 
Epitope  Fluorochrome  Clone  Provider  Catalogue #   Vab/100µL (µL) 
CD36  PE  CB38(NL07)  BD Pharmingen  555455  1 
CD45  APCCy7  HI30  BioLegend  304014  1 
CD71  PECy5  M‐A712   BD Pharmingen  551143  1 
CD235a  PECy7  HI264  BioLegend  349111  1 
 
Cells were resuspended in a final volume of 100 µL, labeled for 30 minutes at 4ºC 
and washed with PBA. DAPI (final concentration of 1 µg/ml) were added and events were 
recorded with a LSR Fortessa (BD Biosciences). Data were analyzed by FlowJo software (BD 
Biosciences). 
Viral vectors and plasmids 
1. Therapeutic and control lentiviral vectors, coRPK and EGFP 
Therapeutic (coRPK) and a control enhanced green fluorescence protein (EGFP) 
vectors used in this thesis are shown on Figure 9. 
The coRPK transgene is a codon optimized version of the coding DNA of PKLR gene 
that produces RPK enzyme. The rest of the sequences of the vector are shared by 
therapeutic and control. Both of them were self-inactivating lentiviral vectors based on 
pCCL lentiviral backbone. Cytomelgalovirus (CMV) promoter drove the expression of the 
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primary transcripts in the packaging cell line. Transgenes (coRPK or EGFP) expression was 
directed under the human phosphoglycerate kinase (PGK) promoter.  
 
Figure 9. Lentiviral vectors used to transduce hematopoietic progenitor cells of PKD mouse model.  
Constructs  were  based  on  pCCL  backbone;  expression  during  viral  production  was  driven  by 
Cytomelgalovirus  (CMV)  promoter.  Transgene  promoter was  human  phosphoglycerate  kinase  (PGK). 
Woodchuck hepatitis virus post‐transcriptional regulatory element mutated (Wpre*) sequence is meant 
to stabilize transgene transcript. 3’ LTR region was mutated (U3) to make it self‐inactivating. EGFP and 
coRPK constructs only differ in the transgene. 
 
This eukaryotic promoter produces stable expression of the interest genes. A 
mutated version of Wpre (woodchuck hepatitis virus post-transcriptional regulatory 
element) was used to stabilize transgene RNA. The mutation included in Wpre sequence 
prevent the production of a truncated 60 amino acid protein derived from the woodchuck 
hepatitis virus X gene involved in liver cancer.123 Viral vectors were packaged using 
pMD2.VSVg envelope. Both vectors were the same used in preclinical studies carried out in 
our lab.124 
2. Short hairpin RNA vectors 
Short hairpin lentiviral vectors were based on Wiznerowicz and Trono constructs.104 
This vector contains the short hairpin sequence under H1 promoter expression and also 
EGFP transgene under human elongation factor-1 alpha (EF1) promoter (Figure 10, A). 
Six different shRNAs were designed against different RPK mRNA regions (Figure 10, 
B). MluI and ClaI restriction sites flanked the short hairpin sequences to clone it into the 
mentioned vector. Another restriction site (XhoI) was included into the hairpin loop to 
corroborate the presence of the specific sequence in the vector after cloning (Figure 10, C). 
the sequences selected had at least 3 mismatches with respect to coRPK to avoid silencing of 
the therapeutic transgene (Figure 10, C, red nucleotides). 
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Figure 10. Viral vector, sequences design and location of shRNAs along PKLR mRNA.  
(A) Scheme of the  lentivirus used to clone shRNAs (B) RPK mRNA divided  in exons and the  location of 
the six shRNAs along  it.  (C) shRNA sequences. Orange: cloning restriction sites. Blue: hairpin  loop and 
XhoI restriction site. Red letters: nucleotides that differ with respect to coRPK mRNA. 
 
3. Lentivirus productions and titration 
Lentiviruses were produced using a third generation set up with HEK293T line as 
packaging cells. Productions were carried out in 150 mm dishes (Corning) with 60-70% of 
cell confluence transferring the different plasmids required by CaCl2 DNA precipitation 
method.  
 Plasmids used were kindly provided by Dr. L. Naldini (HSR-TIGET, Milan, Italy) 
and produced by Plasmid Factory. Plasmids used were: transfer (transgene of interest; 37 
µg/p150), rev plasmid (pRSV-REV; 9 µg/p150), gag and pol plasmid (pMDLg/pRRE; 23.5 
µg/p150) and VSV envelope (pMD2-VSVG; 12.3 µg/p150). Plasmids were mixed with 
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457µl/p150 of CaCl2 2.5 M and 3.2ml/p150 of water. Afterwards, 3.6 ml/p150 of HBS 2x (281 
mM NaCl, 100 mM HEPES, 1.5 mM Na2HPO4, pH 7) were added dropwise to the mix to 
generate Ca2+/DNA- precipitates and this solution was added to the HEK293T cell cultures.  
After 5-6 hours, medium was removed and fresh collecting medium was added 
(IMDM supplemented with 5% HyClone). Supernatant was harvested 48 hours post-
transfection, centrifuged (450 g, 7 minutes) and filtered (0.22 µm, PES, Merck) to eliminate 
cellular rests. Supernatant was concentrated by ultracentrifugation (70000g, 2 hours, 20ºC; 
Optima L-100 XP Ultracentrifugue, Beckman-Coulter) using Ultra-clear tubes (Beckman-
Coulter). Viral pellet was reconstituted on 100-300 µL saline solution (NaCl 0.9%). Viruses 
were titered by serial dilution of the vector (from 10-2 to 10-6) on HEK293T cells (150-
180,000 cells/well on multiple well plate size 24; FALCON). In the case of GFP labeled 
vectors, transducing units (TU) were calculated based on flow cytometry measures 48-72 
hours after transduction applying the following formula. 
ܷܶ
݉ܮ ൌ
ܩܨܲ% 100⁄ ൈ ݈݈ܿ݁	݊ݑܾ݉݁ݎ
௩ܸ௜௥௔௟	௩௘௖௧௢௥
 
Where Vviral vector is the volume of the viral vector stock used for the titration and cell 
number is the number of cells counted in a replicate well at the moment of transduction. 
Viral vectors non-GFP labeled were titered with the same dilution protocol and 
viral copies were measured by qPCR (see Vector copy number determination, Materials 
and Methods): 
ܸ݅ݎ݈ܽ	݌ܽݎݐ݈݅ܿ݁ݏ
݉ܮ ൌ
ܸܥܰ ൈ ݈݈ܿ݁	݊ݑܾ݉݁ݎ
௩ܸ௜௥௔௟	௩௘௖௧௢௥
 
 
4. CRISPR/Cas9 plasmids 
Two different plasmids were used to clone specific guides. Both plasmids had guide 
RNA and RNA scaffold expression driven under U6 promoter. First construct contained also 
Cas9 sequence under SFFV promoter (Figure  11, A) and the second one had Cas9 and 
ZsGreen sequences linked by a P2A (porcine teschovirus-1´s motif that produce co-
translational “cleavage” of both proteins) under CMV promoter (Figure  11, B). Both 
constructs were kindly provided by Dr. Raúl Torres (CNIO, Madrid). 
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Eleven different guides were designed based on Zhang Lab´s program (MIT)125 
against PKLR gene (Figure 11, C). All guide couples named combos had exon 9 guide I in 
common. Combo´s guides are named after the size of the deletion that generates when are 
combined with exon 9 guide I (Figure 11, D). Exons 8 and 11’s guides were only cloned into 
the first construct; exon 9’s guides were cloned in both constructs and combo 1 to 6 guides 
were cloned only into the ZsGreen labeled plasmid. 
 
Figure 11. CRISPR/Cas9 plasmids and guide RNAs design. 
(A) Scheme of no‐labeled CRISPR plasmid,  including guide RNA and Cas9. gRNA: sequences specific to 
each  gene  region.  Scaffold: DNA  sequence  that  generates  the  joined  gRNA  that  includes  crRNA  and 
tracrRNA joined by the linker represented in purple. Scheme includes structure description of the loops 
that  generate  the  3D  folding  of  the  complex  (see  Strategies  to  generate  human  disease  model, 
Introduction).  (B) GFP  labeled  plasmid.  (C) Guide  RNAs  including MIT program  score,  PAM  sequence 
(red) mismatches  (MM) with  respect  to  coRPK  and  the  strand which guide  is  complementary  to.  (D) 
Summary of the guides that compose each pair of combinations for deletion strategy. 
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Genetic delivery tools 
1. Hematopoietic progenitor transduction protocol 
Mouse hematopoietic progenitors (Lin-) were seeded on 6-well plate (FALCON) 
previously treated with RetroNectine (20 µg/ml covering the bottom of the dishes 
overnight; r-fibronectin CH 296, Takara) and pre-stimulated for 24 hours (using medium 
specified in Mouse hematopoietic progenitor medium section, Materials and Methods). 
Then, cells were transduced with the appropriate amount of lentiviral vectors for 24h at 
final volume of 3 ml/condition. Afterwards, cells were washed with PBS and prepared to be 
transplanted, or grown depending on experimental design. In the experiment that included 
a second transduction round, cells were washed prior the second 24 hours transduction. 
Human CD34+ progenitor cells obtained from cord blood were amplified for 24-96 
hours depending on the experiment using the human hematopoietic progenitor medium 
previously specified (see Human hematopoietic progenitor medium section, Materials 
and Methods). Transductions were performed in 96-well plate (FALCON) at final volume of 
200 µL. After 24 hours of transduction, cells were washed with PBS and diluted in the first 
erythroid differentiation medium, also described above (see Erythroid differentiation 
protocol section, Materials and Methods).  
2. Electroporation of primary cells 
Hematopoietic progenitor cells were electroporated with CRISPR/Cas9 plasmids 
previously described using Amaxa Nucleofector I (Lonza) and following manufacturer´s 
protocols. Cells were electroporated in cuvettes (electroporation volume of 100 µL) using 
Human CD34+ Cells kit (Lonza) and U08 electroporation program. Total amount of plasmid 
used was 11.26 µg, hence, when two plasmids were electroporated at the same time, 5.63 µg 
of each were added to the mix. After electroporation, cells were cultured on 24-well plate 
(FALCON) at 2 mL of final volume. In the case of the experiments with selection based on 
GFP reporter, sorting was performed 24 hours after electroporation. Aggregates were 
eliminated before sorting using 40 µm Cell Strainer (FALCON).  
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3. Electroporation of cell lines  
CRISPR/Cas9 plasmids were also used in cell lines. DNA delivery was carried out on 
20 µL volume format using Amaxa 4D-Nucleofector System and Cell line nucleofector 
solution SF (Lonza). Total amount of DNA electroporated was 3 µg (1.5 µg each plasmid in 
the case of using two plasmids at the same time). 2x105 cells were electroporated following 
manufacturer´s protocol. Different programs were used for the different cell lines (Table 5).  
Table 5. Electroporation programs depending on cell type used. 
Cell Line  Electroporation program 
K562  FF‐120 
LCL  EW‐113 
HEK293T  CM‐130 
 
DNA purification and analysis 
1. Analysis of PKLR gene  
Corroboration of gene edit events generated by CRISPR/Cas9 system was carried out 
on PCR amplified DNA. NucleoSpin Tissue kit (Macherey-Nagel) was used to purify 
genomic DNA. Different primer couples were used to amplify edited regions of PKLR exons 
8, 9 and 11. Also, a different primer couple, with forward primer at exon 9 and reverse 
primer at intron 10, was used to amplify the edited region containing the 459 bp deletion 
generated (Table 6). All primers were designed with NCBI/ Primer-BLAST software and 
purchased to Sigma.  
Table 6. Primers used to amplify gene edited regions. 
F= forward primer; R= reverse primer 
Exon  F/R  Sequence (5´ to 3´)  Amplicon size (bp) 
8  F  GAAGGCGTGAAGAGGTGAGG 300 R  AACCCACAGAGTGCCGAAC 
9  F  CAGGGGTTGTGACTGTGACC 295 R  ATTCTGAGCTCCTACCGCAT 
11 guide I  F  CCTCGTTCACCACTTTCTTGC 259 R  GCAGGGAAGGTCTAGGTAGC 
11 guide II  F  ACTTTCTTGCTGTTCTGGGCT 248 R  GCAGGGAAGGTCTAGGTAGC 
E9‐i10  F  ACAGTGTGAGTCCTACAACTTTGA 670 R  CAATGTGCCCAGTGATGCCG 
 
PCR conditions used were the following: genomic DNA (200 ng), dNTPs (0.2 mM), 
MgCl2 (1.5 mM), forward primer (0.2 µM), reverse primer (0.2 µM), TaqGold DNA 
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polymerase (1.25 U) diluted in the specific buffer provided by the manufacturer up to a final 
volume of 50 µL. All reagents were purchased to Applied Biosystems (Thermo-Fisher). PCR 
program was: 95ºC 10 minutes to activate the polymerase, 40 cycles of 95ºC 45 seconds, 60ºC 
45 seconds and 72ºC 2 minutes. Finally, a 10 minutes step at 72ºC for final elongation. 
Agarose (2%; Conda) gels were used to perform electrophoresis of that PCR amplicons. 
Ethidium bromide added to the agarose was used to visualize the DNA using GelDoc XR+ 
Image system (BioRad) 
2. Gene editing evaluation 
Gene editing evaluation was performed by Surveyor assay on the PCR amplicons. 
Between 200 and 400 ng of PCR product were used to generate the hetero-duplex composed 
by wt and edited strands (warming the sample up to 95ºC and letting it cooling 
0.3ºC/second). This new DNA mix was incubated with the surveyor enzyme (IDT) for one 
hour at 42ºC. This enzyme detects single-strand loops generated because of the different 
sizes of edited and wt strands. Novex™ TBE Gels, 10% (Invitrogen) were used to visualize 
edited PCR amplicons. 
Precise deletions generated using guides I and II for exon 9 were also detected 
digesting exon 9 PCR amplicon with BstXI restriction enzyme (37ºC, 1 hour; New England 
BoiLabs). Results were also visualized in 2% agarose gels. 
TOPO TA Cloning (Thermo-Fisher) was used, according to manufacturer´s 
protocol, to clone PCR-amplified DNA fragments of exon 9 after gene editing. These 
fragments were then sequenced by STABVIDA Company using Sanger sequencing. 
Next generation sequencing (NGS) was carried out by STABVIDA Company. PCR 
products were purified using PCR Clean-up magnetic beads (Axygene) according to 
manufacturer´s protocol. The samples were used for library construction using the KAPA 
DNA Library preparation kit for Illumina with KAPA HiFi. The generated DNA fragments 
(DNA libraries) were sequenced with v3 chemistry in the lllumina MiSeq platform, using 
300 bp paired-end sequence reads. Only variants represented in more than a 1% were 
considered. 
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3. Vector copy number determination 
Vector copy number (VCN) was evaluated on peripheral blood cells of mice 
transplanted with hematopoietic progenitors transduced with coRPK or EGFP vectors. DNA 
was extracted from nucleated peripheral blood cells using NucleoSpin Tissue kit (Macherey-
Nagel).  
VCN was also evaluated on individual methyl cellulose colonies. Each colony was 
collected individually, centrifuged and stored at -20ºC. Pellets were lysed with 10 µL of PBS 
and 20 µL of lysis buffer (0.3 mM Tris HCl, pH 7.5; 0.6 mM CaCl2; 1.5% Glycerol; 0.675% 
Tween-20; and 0.3 mg/mL proteinase K) and incubated at 65ºC for 30 minutes, 90ºC for 10 
minutes more and then 4ºC to finish the lysis.  
Quantitative PCR used to calculate VCN was based on the simultaneous 
amplification of  viral region of the transgene and mouse´s titin gene as reference (named 
Ttn). Primers and probes used are showed on Table 7. 
Table 7. Primers and probes used to perform VCN qPCRs. 
F= forward primer; R= reverse primer; P= probe 
Amplicon    Sequence (5´to 3´)  Fluorochrome  Quencher 
 
F  CAGGACTCGGCTTGCTGAAG    
R  TCCCCCGCTTAATACTGACG    
P  CGCACGGCAAGAGGCGAGG 6FAM  BHQ1 
Titin 
F  AAAACGAGCAGTGACGTGAGC    
R  TTCAGTCATGCTGCTAGCGC    
P  TGCACGGAAGCGTCTCGTCTCAGTC Texas Red  BHQ2 
 
Amplifications were performed on a 7500 fast real-time PCR system (Applied 
Biosystems) using ABsolute qPCR Low ROX Mix (Thermo Scientific). 
A double absolute quantification was interpolated on a standard curve generated by 
serial dilutions (1:10 each) of a plasmid that contained templates for both amplicons 
(pRRL.hPGKmGFP.Wpre.Mex5.Titin, kindly provided by Genethon). VCN was calculated 
with the following formula: 
ܸܥܰ ൌ 2 ൈ 	ܿ݋݌݅݁ݏܶ݅ݐ݅݊	ܿ݋݌݅݁ݏ  
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Cytospin preparation 
For cytospin preparations, 100,000 cells were diluted in PBS (containing 20% of 
HyClon; GE Healthcare) and centrifuged (25 g, 4 minutes) on Polysine™Microscope 
Adhesion Slides (Thermo-Fisher) on a Cytospin 2 centrifuge (Shandon). Samples were 
stained with Wright Stain Modified solution (SIGMA) for 3 minutes. Microscope slides were 
washed with water to remove the excess of staining. Olympus BX41 microscope was used to 
take pictures and ImageJ (National Institutes of Health) software to score them.  
Pyruvate kinase activity/hexokinase activity assay 
Two different sample processing were carried out depending on the source of the 
cells. Mouse red blood cells were obtained taking 5 µL from the bottom layer resultant of 
centrifugation at low velocity (450 g, 10 minutes). These 5 µL were diluted 1/20 in 
stabilizing solution (EDTA 2.7 mM, -mercaptoethanol 0.005%). Cell culture pellets were 
directly diluted on stabilizing solution. Independently of sample type, after diluting in 
stabilizing solution, samples were put in liquid nitrogen to fast lysate the cells and stored at -
80ºC.  
Enzymatic activity assay protocols used were modified from the assay already 
described126. Pyruvate kinase/hexokinase (PK/HK) activity assay is based on two 
independent enzymatic reactions, PK and HK activities. As long as erythroblasts mature, 
both PK and HK activities decay. Thus, PK/HK ratio corrects the excess of PK activity 
generated in the most immature erythroblasts. Each activity was measured based on the 
following reactions.  
Pyruvate kinase activity 
ܲܧܲ ൅ ܣܦܲ ࡼࡷሱሮ ܲݕݎݑݒܽݐ݁ ൅ ܣܶܲ 
ܲݕݎݑݒܽݐ݁ ൅ ࡺ࡭ࡰࡴ ௅஽ுሱۛሮ ܮܽܿݐܽݐ݁ ൅ ܰܣܦା 
 
Hexokinase activity 
ܩ݈ݑܿ݋ݏ݁ ൅ ܣܶܲ ࡴࡷሱሮ ܩ6ܲ ൅ ܣܦܲ 
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ܩ6ܲ ൅ ܰܣܦܲ ீ଺௉஽ሱۛ ሮۛ 6	݄ܲ݋ݏ݌݄݋݈݃ݑܿ݋݊݋݈ܽܿݐ݋݊݁ ൅ ࡺ࡭ࡰࡼࡴ ൅ ܪା 
 
Both assays quantify changes on 340 nm absorbance over time. In PK assay, 340 nm 
absorbance decreases over time because of the oxidation of NADH to NAD+, while in HK 
assay, 340 nm absorbance increases over time due to the generation of NADPH.  
For PK assay, reaction mix was prepared on 176 µL (Tris-HCl 0.1 M, EDTA 0.5 mM 
pH 8, MgCl2 0.01 M, KCl 0.1 M, LDH 6 U/mL, ADP 1.5 mM and NADH 0.2 mM). Then, mix 
was incubated with 4 µL of sample at 37ºC for 10 minutes. Finally, 20 µL of PEP (0.1 M) 
were added to each sample and 340 nm absorbance was measured on spectrophotometer. 
Similarly, for HK assay, reaction mix was prepared on 190 µL (Tris-HCl 0.1 M, 
EDTA 0.5 mM pH8, MgCl2 0.01 M, NADP 0.2 mM, ATP 10 mM, Glucose 2 mM and G6PDH 
0.1 U/mL). Then, mix was incubated with 10 µL of sample at 37ºC for 10 minutes and 340 
nm absorbance was measured on spectrophotometer.  
Assays were carried out on flat transparent bottom 96-well plate (FALCON) and 
absorbance at 340 nm was measured for 10 minutes (1 measure each minute) in a 
GeniousPro reader (Tecan).  
Calculations, based on Lambert-Beer law, were also adapted to the low scale assay 
changing the original 1 cm light path (l) to 0.67 cm. A340 (slope of A vs t regression), 
extinction coefficient of NAD(P)H (NAD(P)H) and dilution factor (D) remain like in the 
original protocol.126 
ܷ
݉݅݊ ൌ
∆ܣଷସ଴
݉݅݊ ൈ
1
ߝே஺஽ሺ௉ሻு ൈ
1
݈ ൈ ܦ 
Thus, PK and HK slopes must be operated as it is shown in the next formulas: 
ࡼࡷ						∆ܣଷସ଴ ൈ 1.207 ൈ ሺെ1000ሻ																ࡴࡷ							∆ܣଷସ଴ ൈ 0.483 ൈ ሺ1000ሻ 
Final results were represented as PK/HK ratio. 
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Protein extraction and western blot 
Cells were lysed using lysis buffer (20 mM HEPES, pH 7.5; 100 mM NaCl; 20 mM 
MgCl2; 10 mM EGTA; 40 mM -glycerophosphate; 1% Triton X-100; phenylmethane 
sulfonyl fluoride PMSF 1 mM; protease inhibitor 1x, Complete Mini Protease Inhibitor 
Cocktail, Roche; phosphatase inhibitor 1x, PhosSTOP, Roche). Protein content was 
measured by Bradford method (BioRad Laboratories). 
In order to denaturalize and reduce the protein extracts, samples were boiled using a 
solution 1:9 of -mercaptoethanol and Laemmli buffer (BioRad), for 5 minutes at 95ºC. 
Electrophoresis was performed in 4–15% precast polyacrylamide gels (BioRad) on 
Tris/Glycine/SDS buffer (25 mM Tris, 192 mM Glycine, SDS 0.1%, pH 8.3; BioRad). Protein 
amount used was 30 µg and Precision Plus Protein Standars Dual Color (BioRad) was used as 
molecular weight reference. Trans-Blot Turbo Transfer (protocol MIXED MW, 2.5A, 25V, 7 
minutes; Biorad) system was used to transfer the proteins to nitrocellulose membranes 
(BioRad). BioRad transfer buffer with 20% absolute ethanol was used. 
Transferred membranes were incubated for 1 hour at room temperature with 
blocking buffer (PBS containing 5% skimmed milk, 0.1% Tween-20). Primary antibodies, 
diluted in blocking buffer, were incubated over night at 4 ºC (Table 8). Secondary 
peroxidase conjugated antibodies were incubated for one hour. After incubation of both 
antibodies, three PBS washes were performed. Secondary antibodies were detected with 
Clarity Western ECL (BioRad) following manufacturer´s protocol. ChemiDoc MP System 
(BioRad) was used to detect the chemiluminescence. Quantity One and Image Lab programs 
were used to quantify the bands (BioRad). 
Table 8. Western Blot antibodies used. 
Primary antibodies 
Protein  Clone  Isotype  Provider  Dilution 
‐actin  AC‐15  Mouse IgG  Abcam  1:2,500 
‐tubulin  Polyclonal  Rabbit IgG  Abcam  1:1,000 
GADPH  6C5  Rabbit IgG  Santacruz  1:1,000 
RPK  Polyclonal  Rabbit IgG  CIEMAT 70  1:10,000 
RPK  Polyclonal  Mouse IgG  CIEMAT 70  1:3,000 
Secondary antibodies 
Protein  Isotype  Conjugated  Provider  Dilution 
Mouse IgG  Donkey IgG  HRP  Jackson  1:50,000 
Rabbit IgG  Donkey IgG  HRP  Amersham  1:10,000 
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Patients characterization 
Conventional follow-up of PKD patients is done through periodic peripheral blood 
sampling and analysis of RBC and white blood cell counts, hemoglobin and reticulocytes 
among others. More specialized studies, such as immune system populations, late erythroid 
progenitor profile or circulating hematopoietic progenitor’s content, are not performed 
routinely. All these aspects were addressed here by complete blood count, flow cytometry 
study of hematopoietic subsets and hematopoietic progenitor quantification by semi solid 
media culture. 
1. Comparative complete blood count  
Up to 21 PKD patients and 32 healthy controls were analyzed by complete blood 
count using an automatic hematological counter. Besides, 6 healthy relatives of PKD 
patients were also evaluated to study if one mutated allele could produce changes on 
hematological parameters. Specifically, these relatives were: three mothers, two fathers and 
one brother from three different patients. 
 Red blood cell subsets were the most influenced on PKD. The number of RBC per 
volume, hemoglobin per volume and hematocrit were decreased with respect to control 
samples (Figure 12, A). All these features describe the decrease of the global erythrocyte 
population due to the PK deficit. Alternatively, mean corpuscular volume (MCV) appeared 
increased on PKD samples, probably caused by the presence of immature erythrocytes. 
Based on the same rationale, immature erythrocytes, richer in hemoglobin content, 
increased the corpuscular hemoglobin (MCH) average of PKD samples compared with 
healthy donor and relative samples. All these traits correlate with chronic anemia 
compensated by reticulocytosis.127 The same effect on MCV and MCH was observed in PKD 
mouse model (Figure 19). Finally, no differences were observed in the cell width 
distribution. Overall, these differences permitted the generation of ROC (Receiver 
Operating Characteristic) curves to set thresholds useful to distinguish between PKD 
patients and healthy donors (Figure 12, A: dotted line; B table).  
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Figure 12. Erythroid parameters of PKD patients.  
(A) Values  concerning RBC  subset are  represented divided on healthy  controls  (C), patient´s  relatives 
and PKD patients. Dotted  line represents thresholds established based on ROC curves (nC=32; nPKD=20; 
nRelatives=6; ****P<0.0001, ***P<0.001, *P<0.05)  (B) ROC  curves details based on  selected  thresholds. 
Thresholds were set trying to maximize specificity maintaining good sensitivity. Results represent mean 
values ± standard deviation. 
 
Results 
 
65 
 
Interestingly, relatives showed mean values between the ones found on healthy and 
deficient, but always remaining in the healthy side of the threshold set based on ROC curve. 
As expected, a not mutated allele was able to compensate the PKD phenotype. Nevertheless, 
this tendency if based on 6 samples, an insufficient number to consider it a robust data. 
Myeloid subpopulations and lymphocytes were checked to find unbalances and its 
relation with PKD (Figure 13, A).  
   
Figure 13. Leucocyte and platelet populations of PKD patients.  
 (A) Leucocyte populations measured by hematological counter (nC=30; nPKD=20; nRelatives=6; *P<0.05) of 
healthy controls (C), patient´s relatives and PKD patients. (B) Platelet count comparing the three sample 
types. Results represent mean values ± standard deviation. 
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Among the three subsets measured, lymphocytes, monocytes and granulocytes, only 
monocyte counts showed altered levels with respect to the controls (0.8 ± 0.5 x 103/µL vs 0.5 
± 0.3 x 103/µL, respectively; mean±SD).  
Finally, platelet population counts of PKD patient samples were no different from 
the controls and relatives (Figure 13, B).  
To study deeper these alterations and to better characterize patient samples, a more 
detailed immunophenotyping study was carried out. 
2. PKD patients immunophenotype 
As reported, PKD affects only erythroid subsets. To further analyze the 
characteristics observed in the erythroid and myeloid subsets, a more detailed study was 
performed by flow cytometry. 
 
Figure  14.  Representative  dot  plots  of  flow  cytometry  analysis  of  hematopoietic  progenitor 
populations  from  healthy  donors  and  PKD  patients.  (A)  Erythroid  progenitors.  (B)  Reticulocyte 
percentage based on acridin orange (AO) staining. (C) Hematopoietic progenitors.  
 
First, immature erythroblasts, characterized by the expression of CD71 and CD235a 
antigens were analyzed (Figure 14, A). This cell subpopulation which is practically 
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inexistent in normal conditions (<0.17% in control cells) raised to 2.9% in studied PKD 
patients (Figure 15, A). 
 
In the same way, reticulocyte percentages increased from 0.7% in controls to 7.8% 
in patient samples (Figure 14, B and Figure 15, A). Both increments are the response of the 
stressed bone marrow to compensate the anemia. Despite relatives´ hematological values 
(Hb, hematocrit, etc.) were between healthy and PKD patients, this was not the case for 
reticulocytes and progenitors where PKD relatives showed similar values to healthy donors. 
As performed in RBC counts, two ROC curves, one for each erythroblast population, were 
generated to set thresholds that discriminate healthy from PKD patients (Figure 15, A: 
dotted line; B table). 
   
Figure 15. Erythroid progenitors and mature myeloid populations measured by flow cytometry. 
(A) Erythroid progenitors (CD71+ CD235a+), reticulocytes, monocytes (CD14+) and granulocytes (CD15+). 
Threshold set on erythroid progenitors  (CD71+ CD235a+) and  reticulocytes  (dotted  line) was based on 
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ROC  curves  described  on  (B)  (nC=30;  nPKD=20;  nRelatives=6;  ****P<0.0001,  **P<0.01,  *P<0.05).  Results 
represent mean values ± standard deviation. 
 
Other myeloid subpopulations, monocytes (CD14+) and granulocytes (CD15+) were 
evaluated showing no statistical differences among PKD patients, relatives or healthy donors 
(Figure 15, A). 
Moreover, classic lymphocyte populations were measured: B cells, followed by 
CD19, and T cells, tracked by CD3. Besides, helper T (CD3+ CD4+) and cytotoxic T (CD3+ 
CD8+) cells were also measured. No differences were found between healthy and deficient 
samples (Figure 16). 
   
Figure 16. Lymphocyte populations measured by flow cytometry.  
Cytometry percentages of healthy controls  (C), patient´s  relatives and PKD patients. B cells  (CD19+), T 
lymphocytes (CD3+), T helper lymphocytes (CD3+ CD4+) and T cytotoxic lymphocytes (CD3+ CD8+; nC=30; 
nPKD=20; nRelatives=6). Results represent mean values ± standard deviation. 
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3. Hematopoietic progenitors on peripheral blood 
Flow cytometry was also used to evaluate the presence of hematopoietic progenitors 
circulating in peripheral blood (Figure 14, C). This subset is characterized by CD34+ staining 
and it is normally barely represented on peripheral blood (lower than 0.1% of total cells). 
Although a slightly higher percentage of CD34+ cells in peripheral blood was observed in 
PKD samples (control = 0.06 ± 0.04 %; PKD = 0.09 ± 0.07 %; mean±SD), there were no 
significant differences (Figure 17, A). 
   
Figure 17. Hematopoietic progenitors present in peripheral blood. 
(A) Hematopoietic progenitors present in peripheral blood of healthy controls (C), PKD patients and PKD 
relatives  by  flow  cytometry.  (B)  Total  colonies  forming  units  generated  from  healthy  controls  (C), 
patient´s  relatives  and  PKD  patients.  (C)  CFU‐GM:  granulocyte‐macrophages  populations.  (D)  BFU‐E: 
erythroid committed progenitors (nC=28; nPKD=19; nRelatives=6). Results represent mean values ± standard 
deviation. 
 
The same question was addressed analyzing the colony forming cell content. 
Mononuclear cells purified from peripheral blood were seeded on enriched semi solid 
medium doing triplicates, of 250,000 cells each, to allow the growth of hematopoietic 
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colonies coming from individual progenitors (CFUs). Also, erythropoietin was added to this 
enriched methyl cellulose medium to permit the visualization of erythroid progenitors. 
After 14 days, colonies were scored.  
Although not statistically significant, PKD patient´s samples showed a slight 
increase in total colonies, about 1.3 times higher than the colonies formed by control 
samples (Figure 17, B). Interestingly, that tendency was also found in CD34+ population 
measured by flow cytometry (Figure 17, A). This was also observed on the two different 
progenitor types identified, colony forming unit granulocyte-macrophages (CFU-GM; 
Figure 17, C) and erythroid burst forming unit (BFU-E; Figure 17, D).  
Apart from the data showed before, other correlations were studied between 
severity of the disease (estimated by the hematological values) and other patient 
characteristics, such as mutations and gender.  
Patients studied in this thesis showed more severe phenotype when they were 
double non-missense mutation (NM/NM) versus double missense mutation (M/M). For 
instance, hemoglobin values were: NM/NM= 7 g/dL (n=1, mean±SD), NM/M=10±2 g/dL 
(n=4, mean±SD) and M/M=12±3 (n=11, mean±SD). Nonetheless, the number of patients per 
group was too low, so a higher number of samples would be required to confirm this 
correlation. 
Finally, no significant differences were found comparing severity, represented by 
hemoglobin level, of different genders: male PKD patients = 11±3 g/d (n=11, mean±SD), 
female PKD patients = 12±3 g/d (n=9, mean±SD). 
Definition of the minimal dose of corrected cells to cure PKD  
  To facilitate the applicability of gene therapy for PKD, the definition of the 
minimum corrected cell number required to cure the disease is important to know the 
optimal amount of transduced cells needed to be transplanted in PKD patients. Pre-clinical 
studies demonstrated the curative capacity of coRPK lentiviral vector for PKD in a PK 
deficient mouse model (AcB55). In this previous work, all cured mice showed VCN values 
higher than 1 vector copy per cell.124 Nevertheless, the minimum amount of therapeutic 
vector required to compensate the disease was a question that remained unclear.  
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The following experiment series had the aim of elucidating the VCN threshold above 
which PKD mice show a healthy phenotype. 
1. In vivo PKD correction and its relation with VCNs 
Similarly to the eventual human clinical trial, the basic scheme of the experiments 
was based on ex vivo correction of hematopoietic progenitors and their transplantation into 
conditioned PKD mice. 
Thus, mouse hematopoietic progenitor cells (Lin-) were sorted from total bone 
marrow samples extracted from male PKD mice and transduced as explained (see 
Hematopoietic progenitor transduction protocol, Materials and Methods). Two 
lentiviral vectors were used, the therapeutic coRPK vector and the EGFP vector as control. 
After a 24 hours pre-stimulation period, two transduction rounds (Multiplicity of infection, 
MOI=10) were performed after 0 and 24 hours post pre-stimulation. Six conditioned female 
mice (3 per treatment; two doses of 4.5 grays) were transplanted with 400,000-500,000 
progenitor cells/ mouse. 
 
Figure 18. PK/HK activity from RBC of mice transplanted with transduced hematopoietic progenitors. 
mC: healthy control mouse cells (n=2). hC: healthy control human cells. Measures were normalized with 
respect to the mean of mC samples. (coRPK and EGFP n=3 each; ***P<0.001). Results represent mean 
values ± standard deviation. 
Forty days post-transplant, peripheral blood samples were taken to assay pyruvate 
kinase activity (Figure 18). Mice transduced with therapeutic vector recovered enzymatic 
activity levels comparable to those measured in control mice and human healthy donors, 
while PKD mice transduced with the EGFP vector remain under 50% of activity.  
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Figure 19. Hematological features of PKD mice transplanted with corrected hematopoietic progenitors 
one year post‐transplant of genetically corrected cells. 
(A) Hematological parameters of mice transduced with coRPK  (purple circles) and control EGFP vector 
(green  squares).  Dashed  interval  in  reticulocytes  graph  represents  standard  deviation  of  control 
deficient mice (AcB55). Dotted horizontal lines are the thresholds set based on ROC curves, which values 
are represented on table (B; ***P<0.001, **P<0.01, *P<0.05). Results represent mean values ± standard 
deviation. 
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The experiment was followed up for a year. At the end point, spleen, bone marrow 
and peripheral blood were collected. The study of the hematological parameters of 
peripheral blood at end point revealed a complete correction of the deficient profile (Figure 
19, A). Erythrocyte count, hemoglobin and hematocrit of corrected mice recovered values 
above the threshold stablished by the ROC curves (generated from healthy, C57BL/6, and 
PKD, AcB55, mice samples; Figure 19, B).  
 Also, the volume of the erythrocytes and the amount of hemoglobin per cell 
decreased to normal levels indicating a rescue from the anemic situation (Figure  19, A). 
Correlating with these results, the corrected mice did not present reticulocytosis (Figure 19, 
A). 
Spleen size is a good indicator of the rescue of the disease. PKD mice suffer 
splenomegaly due to the increased splenic activity that have to process all deficient 
erythrocytes. Mice treated with coRPK vector reduced its spleen size and weight to normal 
values (Figure 20). 
 
Figure  20.  Spleen  size  and  weight  of  mice  transplanted  with  control  or  corrected  hematopoietic 
progenitors.  
Size (A) and weight (B) of mice´s spleens transduced with therapeutic vector (coRPK) and control vector 
(EGFP). Dashed interval represents the healthy zone based on the standard deviation of control healthy 
C57BL/6 mice (*P<0.05). Results represent mean values ± standard deviation. 
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Bone marrow samples were taken to elucidate the transduction efficacy and the 
number of transgene copies that produced this correction. Cells extracted from bone 
marrow were cultured on methyl cellulose for 7 days.  
DNA from CFUs was analyzed by qPCR to measure the VCN in each individual 
colony. The analysis of the transduced/non-transduced CFUs showed that all mice within 
coRPK group had near 100% transduced CFUs. In the case of EGFP mice, one animal had 
near 100% transduction while the others had around 70% (Figure 21, A). 
 
Figure  21.  Transduction  efficacy  and  VCN  in  colonies  forming  units  from  bone  marrow  of  mice 
transplanted with control or corrected hematopoietic progenitors. 
(A)  Percentage of CFUs positive  for  the  transgene  among  total  colonies  evaluated by qPCR.  (B) VCN 
evaluated  by  qPCR  of  transduced  colonies.  Number  of  colonies  measured=13‐16.  Colonies  were 
considered  positive when  VCN was  higher  than  0.15  copies  /cell.  Results  represent mean  values  ± 
standard deviation. 
 
The technique used is based on counting the proportion of transduced/non-
transduced CFUs. To confirm the reliability of the qPCR method, the results obtained were 
compared with the percentage of EGFP positive hematopoietic cells in bone marrow and in 
spleen by flow cytometry. Percentage of transduced cells taking into account all the three 
methods together for each EGFP mouse was 83±17%, 49±17% and 75±4%, respectively. CFU 
transduction proportion measured by qPCR and flow cytometry of the bone marrow and 
spleen data were consistent. 
VCN was evaluated individually on each colony by qPCR (Figure 21, B). Despite of 
the fact that the cells transplanted on each mouse came from the same pool of transduced 
cells, VCN slightly varied among the different mice. Nevertheless, all mice transduced with 
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coRPK were corrected meaning that at least 2±1 copies per cell were enough to correct PKD 
phenotype (Figure 21, B). 
With the aim of precisely defining the minimum number of corrected cells to have a 
therapeutic effect and the correcting VCN limit where PKD mice are not capable of 
rescuing the disease, additional experiments were performed covering a large MOI interval. 
The idea was to be able to correlate VCN with either corrected or deficient mice. Thus, 
MOIs from 0.3 to 50 were tested in a new experimental series. 
2. Minimum therapeutic VCN 
The general scheme of this experiment was similar to the previous one, but here, to 
avoid variations, a unique transduction cycle was performed. Moreover, to make the results 
independent of transduction efficacy and engraftment percentage, the final read out was 
done taking into account the VCN. The experimental series were done in two independent 
experiments, one at high MOIs (25 and 50) and another covering a wide spectrum of low 
MOIs (0.3, 1, 3, 10, 25), having MOI=25 group in common. 
For high MOIs experiment, seven male PKD (AcB55) mice were sacrificed and Lin- 
cells were sorted from their bone marrow. After one transduction round with coRPK 
(MOIs: 25, 50) or EGFP (MOI=100), cells were transplanted in conditioned female PKD 
mice (1x106 cells/mouse, 3 mice per each group; two doses of 4.5 grays). VCN and 
hematological parameters were followed for 215 days (Figure 22). 
Reticulocyte percentages of control EGFP mice were mostly two times higher than 
the values obtained in the coRPK transduced ones all over the experiment, indicating that 
mice transduced with the therapeutic vector were corrected (Figure  22). The egress of 
reticulocytes showed a characteristic dynamic: a sharp increase around day 70 followed by 
stabilization, close to healthy values in the case of coRPK mice (Figure 22). 
With respect to the other erythroid parameters, coRPK mouse scores remained 
around the healthy values all over the experiment, while EGFP values fitted with PKD 
values (Figure 22). 
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Figure 22. Erythroid parameters and VCN over  time of mice  transplanted with  control or  corrected 
cells and analyzed up to 215 days post‐transplant (d. p. t). 
Green  line: mice  transduced with EGFP vector. Purple  line: mice  transduced with coRPK MOI 50. Pink 
line: mice  transduced with coRPK MOI 25. Dashed  interval  in  reticulocytes graph  represents standard 
deviation of control deficient mice (AcB55). Dotted horizontal lines are the thresholds set based on ROC 
curves, which values are represented on table B, Figure 19. Results represent mean values ± standard 
deviation. 
 
VCN was evaluated by qPCR from peripheral blood samples along the experiment. 
MOI 25 and 50 mice presented similar and very stable copy/cell values despite the different 
number of viral particles used. For instance, at day 42 post-transplant, MOI 25 VCN was 
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1.07 ± 0.06 meanwhile MOI 50 was 1.27 ± 0.03. Despite VCN fluctuated over time, they 
always continued around 1 copy per cell (Figure 22).  
In the next experiment, lower MOIs were tested (0.3-25; Figure 23).  
 
Figure 23. Hematological parameters over time of mice transplanted with cells transduced with MOIs 
from 0.3 to 25 of coRPK or EGFP. 
Results are represented up to 90 days post‐transplant (d. p. t.). Green line: mice transplanted with cells 
transduced with EGFP vector. Purples lines: mice transplanted with cells transduced with coRPK vector, 
the  darkest  line  represents  the  highest MOI,  25, while  the  lightest  line  represents  the  lowest,  0.3. 
Dashed  interval  in reticulocytes graph represents standard deviation of control deficient mice (AcB55). 
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Dotted horizontal  lines are  the  thresholds set based on ROC curves, which values are  represented on 
table B, Figure 19. Results represent mean values ± standard deviation. 
 
Lin- PK deficient progenitors were sorted and transduced with coRPK (MOIs: 0.3, 1, 
3, 10 and 25) or EGFP (MOI=25). After transduction, cells were transplanted in conditioned 
female PKD mice (1x106 cells/ mouse, 3 mice per each group, except groups MOI 1 and 3 
groups in which 4 mice per group were transplanted). Hematology parameters were 
followed for 90 days showing correction differences since day 30. 
 
MOI 10 and 25 groups showed correction at day 60 while the rest groups remained 
at higher reticulocyte values after a decrease observed at 30 days in all groups, probably due 
to the effect of the hematopoietic conditioning and transplant (Figure  23, reticulocytes. 
Dashed area represents deficient values). Efficacy of the treatment depends not only on the 
MOI used but also of the percentage of engraftment of the transplanted cells reached. Thus, 
correlation of phenotype correction with VCN was only possible being independent of these 
two parameters. 
VCNs of both experiments were evaluated and compared to see the correlation with 
respect of the MOI used (Figure 24).  
 
Figure 24. Correlation between VCN reached in the animals with respect to coRPK MOI used in both 
experiments. 
Light color columns represent results of the  low MOIs experiment (day 30 post‐transplant). Dark color 
columns  represent  results  of  the  high MOIs  experiment  (day  42  post‐transplant).  Results  represent 
mean values ± standard deviation. 
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 As expected, VCN obtained increased progressively with MOI. Moreover, the MOI 
25 group, in common in both experiments, showed comparable VCN values (Figure 24).  
 
Figure 25. VCN versus hematological parameters. 
VCNs obtained in both experiments together. Up: Dotted vertical lines correspond to 0.2 and 0.3 VCNs, 
interval which fits with the minimum therapeutic VCN. Down: Pink columns correspond to 0.2 and 0.3 
VCNs. Orange  line, non‐lineal  correlation. Dashed  interval  in  reticulocytes  graph  represents  standard 
deviation of control deficient mice (AcB55). Dotted horizontal lines are the thresholds set based on ROC 
curves, which values are represented on table B, Figure 19.  
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 Finally, to address the question of minimum number of copies per cell to correct the 
disease, VCNs obtained along all sampling points of both experiment were plotted against 
the different hematological parameters (Figure 25). 
 As happened in the graphs that show the hematological parameters over time, here 
it is also reticulocyte percentage where a clear correlation could be observed (R2=0.868), 
being VCNs between 0.2-0.3 the limit below which mice could not be rescued. The rest of 
parameters also showed PKD phenotype below 0.3 VCN but the disperse distribution of the 
values did not permitted a good correlation (R2<0.5). 
Thus, thanks to these correlations a minimum copy number of coRPK per cell in peripheral 
blood was stablished to cure PKD, being between 0.2 and 0.3. 
PKD model 
  As it has been shown in Patients characterization section, immunophenotyping of 
patient´s cells is possible using small amounts of peripheral blood. However, peripheral 
blood is a poor source of PKD hematopoietic progenitors that are needed to test and improve 
new advanced cell and gene therapies for this disease. From a standard sample of 3 ml of 
peripheral blood barely a few thousands CD34+ cells can be obtained. For a deeper study of 
the disease and to have material enough to test different curative approaches, a new source 
of PKD progenitors is needed. To beat this drawback, PKD-like cells could be generated by 
modifying the gene expression or the genome of healthy hematopoietic progenitor cells. 
 Hence, to address this issue two different approaches were applied. The first was 
based on the use of shRNAs recognizing specific sequences of the RPK mRNA packaged into 
lentiviral vectors. The second approach was based on the transitory electroporation of the 
CRISPR/Cas9 system with specific guides for PKLR gene. Both strategies are meant to 
decrease RPK levels, disrupting either mRNA or directly the progenitor cell genome, 
respectively. 
1. PKD-like cells generated by shRNAs 
1.1 In vitro RPK silencing in K562 cell line	
 The aim of the first strategy was to generate PKD-like cells by silencing RPK mRNA 
expression. As explained in Materials and Methods, six shRNAs were designed to recognize 
Results 
 
81 
 
the wt RPK mRNA sequence and not the therapeutic vector sequence (coRPK). A first 
screening was done with three of the six shRNAs, Sh1, Sh3 and Sh5, targeting exons 11, 1 
and 6, respectively. The designed shRNAs were cloned in a lentiviral vector backbone that 
also expressed the EGFP protein to easily trace transduced cells. As control, a scramble 
shRNA viral vector not recognizing any specific cellular mRNA (Scrb) was developed and 
used in parallel. To validate shRNAs efficacy, a cell line from a human chronic myelogenous 
leukemia (K562) that expresses the RPK isoform was used.  
About 80,000 cells for each condition were transduced (MOI=10) with the three 
different viral vectors expressing shRNAs and Scrb. After amplifying the culture, cells were 
collected to evaluate RPK level by western blot. 
While all shRNAs were able to decrease RPK level, Sh1 and Sh3 seemed to be the 
most effective in reducing RPK production. After Sh1 transduction, RPK was not visible on 
western blot membrane and Sh3 transduction reduced about 80% RPK level compared with 
control Scrb sample (Figure 26). Once these good results were obtained, these three shRNAs 
were selected to continue the screening, discarding Sh2, Sh4 and Sh6. 
 
 
Figure 26. Western blot of K562 cell line interfered with different RPK shRNAs. 
 K562  cell  line expresses endogenous RPK protein. C: non modified K562, non‐transduced  cells;  Scrb: 
cells  transduced with  scramble  vector;  Sh1,  Sh3  and  Sh5,  the  three  different  shRNA  vectors  tested 
(80,000  cells/condition; MOI=10). ‐actin was used  as  loading  control. Quantification was performed 
normalizing with respect to ‐actin and with respect to non‐modified K562 (C). 
 
Another basic requirement to select one of these shRNAs was that they should not 
recognize the codon optimized sequence of coRPK.  
To corroborate this, different cell lines not expressing RPK were first transduced 
with the therapeutic vector (coRPK) and then with the different shRNA-LVs. HL-60 cells, a 
human promyelocytic leukemia cell line, was transduced with coRPK (MOI=10) and, 
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afterwards, transduced with shRNA 1, 3 and 5 (MOI=10). Transduced cells were sorted 
based on the expression of the EGFP reporter expression. 
None of the shRNAs tested were able to prevent coRPK production, meaning that 
any shRNA affected coRPK expression (Figure 27).  
 
 
Figure 27. Western blot of HL‐60 cell line interfered with different RPK shRNAs after being transduced 
with coRPK transgene.  
+: cells transduced with coRPK vector (MOI=10); C: control, non‐transduced cells; Scrb: cells transduced 
with scramble vector; Sh1, Sh3and Sh5: the three different shRNAs tested, (MOI=10). ‐actin was used 
as loading control. Quantification was performed normalizing with respect to ‐actin and with respect to 
non‐modified HL‐60 (C). 
 
To assure that shRNAs were not capable of silencing coRPK, a second cell line was 
transduced at different MOIs of coRPK. HT1080 cells (a routine cell line which does not 
express endogenous RPK) was transduced with decreasing MOIs of 60, 6 and 0.6 of coRPK 
and again transduced with the most potent shRNA (sh1) at constant MOI of 10. RPK 
expression from coRPK vector was visible even in the lowest MOI tested, meaning that Sh1 
did not affect transgene protein production (Figure 28). 
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Figure 28. Western blot of HT1080 cell line transduced with different MOIs of coRPK transgene and 
interfered with Sh1. 
Scrb: cells transduced with scramble vector; Sh1: MOI=10. coRPK: MOIs of 60, 6 and 0.6. Quantification 
was performed normalizing with respect to ‐actin and with respect to non‐modified HT1080 (C). 
 
1.2 PKLR gene silencing in hematopoietic progenitors 
The next step was to study if the developed shRNA system to silence RPK expression 
was efficient in primary human hematopoietic progenitors. In vitro cell line testing showed 
Sh1 as the most potent shRNAs. Therefore, it was the one chosen for these studies. Healthy 
hematopoietic progenitors (CD34+) obtained from cord blood were transduced with the Sh1 
or the Scrb lentiviral vector and put into an in vitro erythroid differentiation protocol.  
A 2-3 weeks erythroid differentiation protocol was used in which different cytokine 
cocktails promoted the hematopoietic progenitors differentiation to become mature 
erythroblasts. In these cultures, RBC maturation can be followed by changes in surface 
markers. CFU-E are CD36+/CD45+/CD71+/CD235a-. Progressively along maturation, 
erythroblasts lose CD45, CD36, later they gain CD235a and finally they lose CD71 (Table 9, 
A).128,129 
However, the in vitro differentiation protocol used here changed slightly the timing 
of the decrease of some surface markers with respect to in vivo normal differentiation. 
Normally, CD45 and CD36 are the first two antigens that pro-erythroblasts lose.129 Thus, 
when CD71+ reach its highest expression, cells are completely negative for CD45 and mostly 
for CD36 (Table 9, A, I). After reaching maximum CD235a expression, differentiation stages 
are divided in three subpopulations based on CD71 decrease (Table 9, A, II-IV).  
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Table 9. Erythroid maturation immunophenotypes. 
A. Immunophenotype along in vivo erythroid maturation 
 
  CD235  CD71  CD36  CD45 
I  ‐  +  +  + 
II  +  +  mid  ‐ 
III  +  mid  low  ‐ 
IV  +  ‐  ‐  ‐ 
B. Immunophenotype along in vitro erythroid maturation 
 
  CD235  CD71  CD36  CD45 
I  ‐  +  +  + 
II  +  +  +  mid 
III  +  mid  mid  low 
IV  +  ‐  ‐  ‐ 
 
 In the in vitro differentiation used, CD36 and CD45 expression could be found 
within the CD71+ population. To illustrate this, the immunophenotype of three different 
samples is shown Figure 29. 
The first two columns are primary cells that were obtained from a mobilized 
peripheral blood apheresis of a healthy donor and from cord blood. In both cases, most cells 
were already CD36 and CD45 negative. Populations II (orange), III (purple) and IV (red) 
were established depending on CD71 content (Table 9, A). On the other hand, the third 
sample corresponds with an in vitro erythroid differentiation of primary CD34+ cells. The 
CD36/CD45 dotplots showed a clear transition from CD45mid/CD36+ to CD45-/CD36- (Table 
9, B, red square). Additionally, this transition fitted with the decrease of CD71 (Figure 29, 
right side). Another difference was that most cells found on the first two samples, followed 
by the side histograms, were already CD71- (IV) while in the in vitro differentiation the 
main cell population was subpopulation III (Figure 29, histograms). 
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Figure 29. Erythroid lineage profile of in vivo and in vitro samples.  
Mobilized: sample obtained from apheresis of healthy mobilized peripheral blood. Cord blood: erythroid 
lineage  obtained  from  healthy  cord  blood.  In  vitro:  erythroid  lineage  obtained  from  in  vitro 
differentiated  after  14  days  from  hematopoietic  progenitors  obtained  from  cord  blood  (A)  CD71 
decrease over maturation with respect to CD235a population. (B) CD36/CD45 decrease over maturation. 
Right‐side histogram: cell distribution among  total cells on each sample. Erythroid subpopulations are 
represented in orange (II), purple (III) and red (IV). 
 
Therefore, the criterion followed for in vitro erythroid maturation was not based 
just on CD71 decrease but also on CD36 and CD45 changes. (Table 9, B). Thus, II, III and IV 
in vitro subpopulations do not correspond exactly with their in vivo homologues, but in 
both cases represent the same erythroid maturation stages. Hereinafter, II, III and IV sub-
populations must be understood as in vitro subpopulations. 
After 14 days, cell cultures obtained from the CD34+ cells transduced with the 
interference lentiviruses were already composed by erythroid cells and its differentiation 
stage was evaluated by immunophenotype. 
Flow cytometry analysis was based on the following gating strategy. First, GFP+ 
(interfered) and GFP– (non-interfered) populations were gated separately (Figure 30, A). 
Then, CD36mid/- CD45mid/- populations were selected (Figure 30, B). Afterwards, following 
the criterion previously explained (Table 9, B), populations II 
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(CD235a+/CD71+/CD36+/CD45mid), III (CD235a+/CD71mid/CD36mid/CD45low) and IV 
(CD235a+/CD71-/CD36-/CD45-) were gated on a CD71/CD235a dot-plot (Figure 30, C). This 
was finally back-gated on the CD36/CD45 plot following the same color code (Figure 30, B). 
 
Figure 30. Gating strategy of transduced hematopoietic progenitors after differentiated to erythroid 
lineage. 
Progenitors differentiated after Scrb transduction have been used as example on this scheme  (A) GFP 
positive and negative selection: erythroid maturations of both populations were analyzed separately. (B) 
CD36/CD45 dot‐plots.  (C) CD71 vs. CD235a where  II  (orange),  III  (purple) and  IV  (red)  subpopulations 
were gated and then back‐gated in (B). 
 
Both healthy (GFP-) and deficient (GFP+) cells could be differentiated along the 
erythroid lineage and studied under exactly the same conditions. 
Erythroid profile of cells transduced with Sh1 and Scrb lentiviruses were followed, 
being Sh1+ and Scrb+ the GFP positive fraction of each culture and Sh1- and Scrb- their GFP 
negative counterparts (Figure 31, A and B). 
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Figure 31. Hematopoietic progenitors transduced with either Sh1 or scramble (Scrb) lentiviral vector 
and differentiated to erythroid lineage.  
(A) Total erythroid cells (CD235a+ within CD36/CD45, Figure 30, B) out of total cells. Sh1+ and Sh1‐ are 
the GFP+ and GFP‐  fractions of cell culture transduced with Sh1. Scrb+ and Scrb‐ correspond with GFP+ 
and GFP‐ fractions of cells transduced with the scramble shRNA control. These populations include II, III 
and  IV  fractions. Measures are based on cytometry percentages and normalized with  respect  to Scrb‐ 
percentage, which  is  consider  =100%  (***P<0.001,  *P<0.05;  n=9).  (B)  Erythroid maturation  stages  II 
(orange),  III  (purple) and  IV  (red) percentages within CD235a+ population  (n=9).  (C‐D) Representative 
cytospin micrographs  from cultures after Sh1  (C) or Scrb  (D) transduction and differentiation. Pictures 
show GFP+ fractions that were sorted to isolate transduced cells. (E) Quantification of cell types present 
on cytospin preparations distinguishing basophilic erythroblast (C, 1) polychromatophilic erythroblast (C, 
2), orthochromatic erythroblast (C, 3) and reticulocytes (Sh1 n=2, Scrb n=2). 
 Small variations among the different experiments were observed due to differences 
in the efficacy of erythroid differentiation. To correct these technical variations, each 
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sample was normalized with respect to the Scrb– samples (in theory, the most similar to the 
wild type) of each experiment. 
Total Sh1+ cells that reached erythroid lineage were less than 50% obtained 
transducing with Scrb vector (Figure 31, A). This decrease can fitted with the metabolic 
alteration induced because of PKLR gene silencing. On the other hand, a higher erythroid 
population was expected on Sh1- population, as long as they were not interfered (Figure 31, 
A). 
 Regarding the hypothesis that PKD could unbalance erythroid II-IV 
subpopulations, the different transduced cells were compared. If PK activity is crucial for 
moving towards the final erythroid stages, an accumulation of subpopulations II or III 
would be expected. After flow cytometry characterization, significant differences could not 
be found among II-IV subpopulations. Despite Scrb- cells showed a tendency of having 
higher IV proportion than to Sh1+ population, there were not statistical differences among 
any of the samples, either GFP+ or GFP- (Figure 31, B). This lack of differences was also 
observed in cytospin samples. Before performing cytospin preparation, cells were selected 
based on GFP expression by sorting to enrich cultures on transduced cells. There was a 
similar erythroblast type distribution among Scrb+ and Sh1+ samples (Figure 31, E). 
In theory, none of the populations called negative (Sh1- and Scrb-) neither Scrb+ 
should be different because none of them have shRNA silencing RPK. However, Sh1- was 
significantly different from Scrb- (Figure 31, A).  
A more detailed study of the transduction efficiency and of the progress of the 
transduced cells along the differentiation protocol was performed. Approximately, 10-times 
lower transduction efficiencies were obtained with the sh1 vector than with Scrb vector 
(n=11). In addition, a EGFP decay (representative experiment: Figure 32, A and B) revealed 
that the apparent EGFP loss was due to a differential growth capacity of transduced versus 
non-transduced cells (Figure 32, C and D). Fold increase of GFP- fractions were a little bit 
higher than GFP+ (Figure 32, E), which in long term decreased the percentage of transduced 
cells and limited the number of PKD-like cells available in the cultures. 
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Figure 32. GFP+ decrease observed after shRNA transduction.  
Erythroid differentiation began at day 1 post transduction. (A) GFP percentage of cells transduced with 
Sh1 (purple) and Scrb (green) over time. (B) Closer view of GFP+ decay of cells transduced with Sh1. (C) 
Total cell count along erythroid differentiation. Dark purple: GFP+ fraction of cells transduced with Sh1; 
light purple: GFP‐  fraction of  cells  transduced with Sh1; dark green: GFP+  fraction of  cells  transduced 
with Scrb; light green: GFP‐ fraction of cells transduced with Scrb. (D) Closer view of cell count increase 
of GFP+ fraction.  (E) Fold  increase of cell population over time. Color code used matches with the one 
described  in  (C).  Due  to  the  different  GFP  %  among  experiments,  only  2  experiments  (out  of  11) 
transduced with the same vector batch are showed in this figure.  
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Finally, to avoid the problem of the different growth capacity, cells were sorted by 
GFP and differentiated toward erythroid lineage. Cells silenced with Sh1 decreased PK 
activity to almost 50%, confirming the inhibition of the RPK mRNA and making Sh1+ 
modified cells PKD deficient (Figure 33). 
 
 
Figure 33. PK/HK activity of cells transduced with Sh1 and Scrb vectors after erythroid differentiation.  
Green  circles:  cells  transduced  with  Sh1  vector.  Red  triangles:  cells  transduced  with  Scrb  vector. 
Measures are normalized with respect to Scrb (** P<0.01; Sh1 n=2; Scrb n=3) 
 
2. Generation of PKD-like cells using CRISPR/Cas9 system 
As a second strategy, a genomic knockout of the PKLR gene using CRISPR/Cas9 
editing tools was addressed. Unlike shRNAs, CRISPR affects directly the genome, modifying 
the selected gene permanently. The first question to consider was what region of PKLR 
should be edited to generate a good disruption of the gene. Thus, an initial in silico study 
was performed. 
2.1 PKD mutations study, in silico research of mutation clusters  
Among the considered options, a first one to take into account was to directly affect 
the ATG initial codon region. Consequently, no mRNA would be expected. However, this 
could be considered an artificial situation since it has not been described in PKD patients. 
An alternative strategy that could have a more disease modelling outcome was disrupting 
regions important for enzyme function.  
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While a precise region-importance relationship has not been stablished, a good 
indicator of this could be the number of mutations found in PKD patients reported in each 
exon of the PKLR gene. 
PKD mutations are differentially distributed along the PKLR gene. Among all, exons 
8, 9 and 11 are the ones with more than 30 different mutations reported (Figure 34, A). 
 
Figure 34. Guide RNAs design to target PKLR gene. 
(A) Number of mutations reported in each exon. Green (exon 8), orange (exon 9) and purple (exon 11) 
are the exons with more than 30 different mutations. (B) Horizontal lines represent each exon. Vertical 
lines and arrows are reported mutations, corresponding to one or more than one nucleotide affected, 
respectively. Vertical red dashed lines represent predicted cut sites of guide RNAs selected. (C) Selected 
guides.  Score  based  on  Zhang’s  Lab  (MIT)  software.  Sequences  are written  on  5’‐3’  orientation  and 
include PAM region  (red). Mismatches with respect  to coRPK are  the number of nucleotides different 
from the therapeutic sequence. Strand column indicates if the guide binds to direct or complementary 
DNA strand. 
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 Consequently, these were the exons chosen to be the target of the gene edit. Several 
guides for these three exons were designed using Zhang´s Lab (MIT) software.125 Among 
them, only guides with more than 3 mismatches with respect to the coRPK transgene 
sequence were selected. 
Two guides for each exon were selected. Major selection criterion was their 
proximity to mutation clusters (especially in the case of exons 8 and 9; Figure 34, B). 
Furthermore, selected-guide’s score was above 60 points out of 100 and had at least 3 
mismatches with respect to coRPK, meaning that in theory do not recognize the therapeutic 
vector (Figure 34, C).  
2.2 Efficacy of guide RNAs in vitro  
Six selected guides were electroporated into human lymphoblastoid cells (LCL), to 
test guide activity. Each electroporated construct contained a guide under U6 promoter and 
the Cas9 cDNA under the CMV promoter. 
After electroporation, cells were amplified in vitro for 6 days and then harvested for 
DNA isolation. PCR of the different exons was performed and then surveyor assay was 
applied to those amplicons (see Gene editing evaluation section, Materials and Methods). 
Expected bands were not clearly visible in all the samples of surveyor assay (Figure 
35, A). Exon 8 guide I showed a unique band between the two expected ones and guide II 
did not show any clear pattern. On the contrary, the two guides designed for exon 9 showed 
the expected band pattern. Finally, in spite of exon 11 guide I surveyor showed some bands 
that could fit with the gene edit expected, other bands were also present, making these 
results less clear than those obtained in exon 9. In addition, two different parental bands 
(about 270 and 300 bp) appeared after editing with exon 11 guide II (Figure 35, A, last 
column), probably due to unspecific amplification. 
The same experiment was performed on CD34+ hematopoietic progenitors purified 
from healthy cord blood samples. Surveyor assays presented results pretty similar to the ones 
obtained previously with LCL cells (Figure 35, B). Again, guide I for exon 8 showed a band 
between the expected sizes and guide II for this exon gave no clear result. On the other 
hand, the good results obtained for exon 9 were reproduced here on primary cells. No clear 
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pattern was observed after exon 11 edit. Because of exon 8 guides did not give a clear 
pattern and exon 11 guides did not produce the expected pattern, they were not selected as 
candidates for knocking out the PKLR gene. Thus, exon 9 guides were the chosen ones for 
the next experiments. 
 
Figure 35. Surveyor assay after gene editing of a cell line and primary cells. 
Surveyor assay on LCL cells  (A) and on primary CD34+ cells  (B) electroporated with 6 different guides, 
named  I  and  II  for  each  exon.  Wt:  non  electroporated  cells.  Red  triangles:  represent  bands  that 
correspond with the theoretical sizes expected. Blue triangles: non‐cut band that corresponds with the 
wt PCR amplicon size. Expected bands: Exon 8 (300 bp amplicon) guide I: 166 + 134 bp, guide II: 155 + 
145  bp;  exon  9  (295  bp  amplicon)  guide  I:  160  +  135  bp,  guide  II:  191  +  104  bp;  exon  11  (259  bp 
amplicon) guide I: 177+ 82 bp, guide II: 143 + 116 bp. Lanes marked with * correspond to different gels 
than the rest where result was clearer.  
 
 Although exon 9 guides showed good performance cutting DNA, there were still a 
big proportion of non-edited cells, represented by the parental band on surveyor assays 
(Figure 35, A and B, 294 bp band). This problem was probably due to the fact that not all the 
cells were correctly electroporated. 
 To corroborate this, the same guides were cloned into a plasmid which contained 
the Cas9 linked to ZsGreen, a reporter gene, by a P2A (motif that allows co-translational 
“cleavage” of both proteins at equimolar levels). Besides, the plasmid also contained the U6 
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promoter to express the guide RNAs selected. Hence, just one plasmid was required to 
introduce the guide RNA, Cas9 and the reporter ZsGreen. 
Taking advantage of this fluorescence labeling, GFP+ sorted cells would be enriched 
on the edited population.  
Based on this strategy, 293T cells were electroporated with exon 9 guides. Also, a 
50/50 mix of both guides was used. 72h after electroporation, cells were sorted and GFP+ 
cells were amplified (Figure 36, A). 
 
Figure 36. Sorting and analysis of 293T cells edited by guides I, II and I+II. 
 (A) Sorting of GFP+  cells. C,  control  cells electroporated with a plasmid  containing Cas9‐P2A‐ZsGreen 
without  any  guide.  I  and  II,  cells  electroporated with  the  guides  and  Cas9‐P2A‐ZsGreen.  530/40  vs 
580/30  nm  dot‐plot was  used  to  distinguish GFP  fluorescence  from  auto  fluorescence.  (B)  Surveyor 
assay  to  check  gene  editing  produced  by  electroporating  guide  I,  guide  II  and  both  together  (I+II). 
Triangles  fit with  the band sizes expected.  (C) Scheme of  the band patterns  that appeared when cells 
were electroporated with the guides both separately or at the same time. 
 
DNA was extracted and amplification of the region of interest was performed by 
PCR. Surveyor assay of this PCR amplicons showed that guide I and II presented a good 
performance, with efficacies of 40% and 59%, respectively, quantified by densitometry. 
(Figure 36, B). Interestingly, when both guides were electroporated at the same time, a cut 
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pattern different from the two generated with the guides separately was observed (Figure 
36, B, I +II). As can be seen in the scheme (Figure 36, C), this combined pattern fitted with a 
deletion between both guides. The fact that the other bands (Figure 36, B and C, red and 
orange bands, 135 and 192 bp, respectively) did not appear on that sample suggested that the 
proportion of strands cut with a single guide was very low.  
2.3 Characterization of guides designed for exon 9 
In order to archive a deeper knowledge of the events generated with the different 
guides and their combination, PCR products of the modified regions were cloned into 
bacterial plasmids (see Gene editing evaluation section, Materials and Methods).  
In principle, each amplified bacterial colony contained one event present in the 
PCR. Individual colonies were sequenced by Sanger method. Twenty five colonies were 
sequenced for guide I (Figure 37, A), 22 for guide II (Figure 37, B) and 15 for the 
combination of the two guides (Figure 37, C). 
 
Figure 37. Gene editing events found on 293T cells electroporated with exon 9 guides. 
(A) 293T  cells electroporated with guide  I. First  row  corresponds  to wild  type  sequence,  the  rest are 
altered  sequences.  Dark  blue:  PAM  sequence;  light  blue:  guide  sequence;  vertical  line:  expected 
cleavage region.  (B) 293T cells electroporated with guide  II. Dark purple: PAM sequence;  light purple: 
guide  sequence.  (C)  The  same  cell  line  electroporated with  the  two  guides  at  the  same  time.  Color 
legend is the same as (A) and (B). Red: altered nucleotides, medium dash means deleted nucleotide. 
 
As expected, the use of single guides produced multiple deletions and insertions, 
around cutting site. Using guide I, 80% of the colonies presented an insertion (A) and a 5 bp 
deletion in the rest (Figure 37, A). On the other hand, the use of guide II produced different 
size deletions: 3, 7, 12, 14, 19, 22 and 90 bp around the expected cut site (Figure 37, B). 
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Interestingly, the only event detected when both guides were used at the same time 
was a 31 bp deletion. This 31 bp deletion matched with the theoretical precise deletion 
between nucleotides 3rd and 4th (counting from PAM) of both guides. Despite having 
sequenced less than 20 colonies, this result, together with the obtained on the surveyor 
assay (Figure 36, B), suggested that the use of two guides at the same time favors the precise 
deletion of the DNA between them. This strategy could be a good way to control gene 
editing events that happen after nuclease activity and the subsequent repair by non-
homologous end joining machinery. 
Moreover, the precise deletion generated a stop codon 72 nucleotides after the 
joining point (Figure 38, A). Hence, even in the case of a stable mRNA, approximately one 
third of the amino acid sequence would be disrupted, including regions essential for the 
tetramer interaction (Figure 38, B). 
 
Figure 38. Theoretical gene edit and resulting protein produced by guides I + II at exon 9.  
(A) Up, Exon 9 PKLR gene. Blue highlight  is guide  I sequence;  red highlight  is guide  II sequence. PAM 
sequences are marked in darker colors. Dashed line, theoretical cut produced by Cas9. Down, sequence 
after precise deletion. Purple, new amino acid sequence produced after precise deletion. Dark purple, 
premature stop codon. (B) PK monomer (left) and tetramer (right); blue surface represent regions that 
conserve wt amino acid sequence, red sticks are amino acid changed after deletion.  (Model based on 
PDB: 2VGB 18). 
  
To further explore the possibilities of controlling gene edit with the CRISPR/Cas9 
system using two guides at the same time, 5 new guide combinations were generated.  
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2.4 Analysis of the deletion efficacy using two guides simultaneously  
Based on the idea of generating controlled events deleting regions between guides, 5 
different additional combinations were tested. These new combinations, together with the 
first one (31bp), hereinafter called combos, were meant to generate deletions of different 
sizes, of approximately 10, 30, 60, 120, 240 and 480 bp (Table 10). All the combos shared 
guide I, so every deletion was performed starting from PKLR exon 9 (Figure 39, A). 
Table 10. Deletion distances using 6 guide combinations. 
Name  Combo 1  Combo 2  Combo 3  Combo 4  Combo 5  Combo 6 
Planned distance  10  30  60  120  240  480 
Real Distance  8  31  63  119  239  490 
 
Guides were cloned in the same construct containing Cas9-P2A-ZsGreen to take 
advantage of the sorting strategy. Pairs of guides were electroporated into K562 cells. 
Thanks to the endogenous RPK expression of this cell line, the efficacy of gene editing could 
be also corroborated checking the decrease on protein production. Again, GFP+ cells were 
sorted to enrich edited population. DNA was isolated to verify the deletion and protein was 
extracted to evaluate the effect at protein level. 
Combos 2 to 6 presented smaller PCR amplicons compared to control one that 
perfectly corresponded with the expected deletions (Figure 39, B). Alternatively, combo 1 
deletion was too small to be observed due to the resolution of the gel used. In any case, GFP 
selection was confirmed as a very effective selection method since wt band was not visible 
in any of the deletions. 
Western blot analysis showed that RPK protein was almost completely eliminated in 
all combos (Figure 39, C) meaning that the edited region was crucial for protein generation.  
The results observed were clear in terms of PCR amplicon sizes and in terms of 
protein production. Nevertheless, to deeply analyze how precise was the removal of the 
DNA sequence between the guides, the amplicons were deep sequenced by next generation 
sequencing. 
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Figure 39. DNA and protein analysis of K562 cells electroporated with 6 guide pairs. 
 (A) Scheme of 6  combos  tested.  Light blue: PCR amplicon used  for  the analysis of  combos 1‐5; Dark 
blue: PCR amplicon used for combo 6 analysis. In purple: PKLR gene, exons are represented as boxes and 
introns  as  horizontal  lines. Orange  vertical  lines:  position  of  the  guides  used. Numbers  above  black 
horizontal lines are the size of the deletion generated in each combo. (B) PCR amplicons of exon 9 from 
different  combos.  Up:  combo  names.  C:  control  sample,  K562  cells  electroporated  with  Cas9‐P2A‐
ZsGreen without guides and sorted. Red:  size of  the precise deletion. Combos 1  to 5 were evaluated 
performing a 320 bp PCR meanwhile combo 6 were checked by a 700 bp PCR. (C) Western blot of RPK 
from  combos. Wt:  non‐electroporated  K562  cells.  C:  control  sample,  K562  cells  electroporated with 
Cas9‐P2A‐ZsGreen without  guides  and  sorted.  Red:  sizes  of  RPK  protein,  complete  (62  kDa)  or  after 
physiological N‐terminal excision (57 kDa). GAPDH and ‐tubulin were used as loading control. 
 
The prevalence of the precise deletion as the most represented event was maintained 
along all tested distances except in the 8 bp deletion (Figure 40). A deeper study of the 
events generated trying to produce the 8 bp deletion demonstrated that all of them were 
caused by guide I action alone (Figure 40, A, guide I is represented in blue). In fact, double 
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strand break generated by guide I also altered the other guide sequence (Figure 40, A, 
orange), preventing guide 8 joining and, hence, not making possible the precise deletion. 
The combination of guide I and guide II, also named combo 2, showed two unique 
events. Precise deletion (the 31 bp removal, Figure 38, A) already detected by Sanger 
sequencing (Figure 37, C), and a 32 bp deletion. Precise deletion represented 87% of events 
recorded. The other event registered, a 32 bp deletion, shared the 31 bp deletion with the 
most represented minus an adenosine located 5’ of the guide I cut (Figure 40, B).  
Combos 2 to 6 showed the precise deletion as the most frequent event (69-96%) 
produced (Figure 40, B-F). In combos 3 to 6 (63-490bp deletions) additional indels 
(insertion/deletion events) near the precise deletion (Figure 40, B-F, IND) were found. 
Furthermore, some indels were found produced by guides separately in combos 3 to 6 
(Figure 40, SGI, above wt and guides sequences). 
Unfortunately, this strategy of double mapping does not permit the comparison of 
the frequencies of the events produced by the two guides together (Precise deletion and 
IND) and the frequencies of guides that acted individually (SGI). However, this could be 
indirectly addressed comparing the proportion of different sizes PCR products. Thus, SGI 
had to be barely represented as long as wild type PCR band was not visible in the agarose 
gels (Figure 39, B). 
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Figure 40. Variants and its frequency of combos 1‐6 analyzed by NGS. 
Within  each  combo  scheme  there  are  three  differentiated  parts.  Up:  indels  generated  by  guides 
individually, named single guides indels (SGI). Middle: wt sequence and the guides used for each combo. 
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Down:  Precise  deletion  sequence  and  its  frequency.  Bottom:  indels  near  precise  deletion  and  its 
frequency (IND). NGS was performed for two independent experiments per each deletion distance. 
 
The use of guide pairs was an effective strategy to control gen editing events in 
distances from 31 to 490 bp. Moreover, the proportion of precise deletion was not affected 
by the progressive increase of the distance between guides (Figure 41). 
 
Figure 41. Precise deletion compared with the distance removed. 
(A) Frequency of the variants found in the deletions. Purple bars: Precise deletion. Different type of blue 
bars:  Indels  near  precise deletion  (IND). Different  type of  orange  bars:  indels  generated  by  just one 
guide  (SGI).  (B)  Proportion  of  precise  deletion  and  indels  near  precise  deletion with  respect  of  the 
distance between the guides used. 
 
2.5 Generating PKD-like cells from hematopoietic progenitors 
Having evaluated the possible outcomes of gene editing on K562 cells, the next step 
was to apply the strategy to primary cells. It was already demonstrated that any of the guide 
combinations tested were able to disrupt RPK production with a good performance. The 
combination chosen was the combo 2, the guides that generated a 31 bp deletion in exon 9 
(guide I and guide II, hereafter named I+II) because the events generated were tightly 
controlled: only two type of deletions (31 and 32 bp) according to NGS data (Figure 40, B). 
Furthermore, both deletions altered the amino acid sequence, generating premature stop 
codons after 24 amino acids in the case of 31 bp deletion and after 5 amino acids in 32 bp 
deletion case (Figure 42, A).  
Hematopoietic progenitor cells (CD34+) obtained from healthy cord blood samples 
were electroporated with guides I + II at the same time. Twenty four hours after 
electroporation, cells were sorted based on GFP expression. Then, a two week erythroid 
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differentiation protocol was performed. Cells were analyzed in terms of DNA editing 
efficacy, immunophenotype, cytomorphology and pyruvate kinase activity. 
 
Figure 42. gDNA study of primary edited cells after erythroid differentiation.  
(A) Amino acid sequence resultant after 31 and 32 bp deletions. Red amino acids are the alerted ones 
with  respect  to  the wt.  Both  deletions  generate  premature  stop  codons  represented  by  “…”  on  red 
background.  (B) Exon 9 PCR amplicons  from different experiments.  I +  II: edited cells. C: control cells 
electroporated with Cas9‐ P2A‐ZsGreen without guides.  I +  II and C are  the GFP+  fraction  selected by 
sorting. Wt: non‐electroporated cells. (C) Sequences of the two main deletions produced after gene edit. 
Blue: region covered by guide  I. Purple: region covered by guide  II. Sequence  from dark‐blue  to dark‐
purple: BstXI  recognition  site.  Light  red: differential nucleotide, not present  in 32 bp deletion,  that  is 
required  for  BstXI  recognition.  (D)  Lane  1,  molecular  weight  reference.  2‐4  lanes:  hematopoietic 
progenitor cells differentiated in vitro toward erythroid lineage and edited with guides I + II. 5‐7 lanes: 
control cells electroporated with Cas9‐P2A‐ZsGreen without guides. GFP, + or – fractions separated by 
sorting. + or – BstXI, treated or not with the enzyme. Red triangles, DNA cut after enzyme digestion. (E) 
Next  generation  sequencing  results  from  two  edited  DNA  samples,  colors  represent  each  of  the 
deletions found named Del 31, Del 32, Del 40 and Del 55. 
 
DNA edit was the first checkpoint to validate that the cells were edited. The use of 
these two guides generates a 31/32 bp deletion easy to detect by PCR due to decreased band 
size with respect to wt sequence. This was consistently observed in every independent 
experiment carried out. Five of them are presented on Figure 42, B.  
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The precise deletion generated a new restriction site in the DNA. Thus, a fast way to 
corroborate the presence of this 31 bp deletion was based on the presence of a new BstXI 
site. It appears only in the case of the precise deletion (31 bp) but not in the other deletion 
(32 bp; Figure 42, C). After digesting the PCR product with this restriction enzyme, DNA 
cut pattern appeared in cells electroporated with guides I + II (Figure 42, D, lane 3). It was 
also possible to observe a faint cut on the GFP- fraction, meaning that maybe some edited 
cells were not GFP at sorting step (Figure 42, D, lane 4). 
Two edited samples, differentiated to erythroid lineage, were also analyzed by NGS. 
Interestingly, on primary cells the same two deletions appeared almost in the same 
proportion as in K562 cell line: about 83% were precise deletion (31 bp) and 16% were Del 
32. In one of the samples, two other deletions were also found (Del 40 and Del 55) in a low 
frequency, 1.6 and 1%, respectively (Figure 42, E). 
The next step was to find out if this knockout of PKLR gene affected in vitro 
maturation of the hematopoietic progenitors to mature erythroblast forms. As it has been 
commented previously, hematopoietic progenitors, after being electroporated with guides I 
+ II and sorted, were differentiated in vitro based on the 3 weeks protocol explained (n=6; 
see Erythroid differentiation protocol, Materials and Methods). 
Cytometry analysis was performed to measure the proportion of cells within the 
transition from CD36+/CD45mid to CD36-/CD45- (all of them CD235a+), which represents the 
proportion of cells maturing along the erythroid lineage (Figure 43). Gating strategy was the 
same used on shRNA section without the first gating based on GFP since at the end of 
differentiation protocol all cells were GFP negative (Figure 30, B and C). 
 In parallel, hematopoietic progenitors from bone marrow sample of a PKD patient 
(c.359C>T, exon 4/ c.1168G>A, exon 9) was differentiated in vitro to validate that the model 
was representing correctly the disease.  
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Figure 43. Hematopoietic cells edited and differentiated towards erythroid lineage. 
PKD:  cells differentiated  from patient bone marrow  sample.  I  +  II:  cells  electroporated with  the  two 
guides. C:  control  cells electroporated with Cas9‐P2A‐ZsGreen without guides. + or  ‐: GFP positive or 
negative fraction separated by sorting. Wt: non‐electroporated/sorted cells. (A and C) Cytometry results 
for CD36/CD45 staining. Gray: histogram that represents the cell distribution along CD36 staining. (B and 
D) Cytometry  results  for CD71/CD235a  staining. Gray: histogram  that  represents  the  cell distribution 
along CD71 staining (n=6). (E) Cytospin after 14 days of erythroid differentiation. 1: polychromatophilic 
erythroblast; 2: orthochromatic erythroblast; 3: reticulocyte. 
 
As in the shRNA study, results were normalized with respect to the control, C- 
(GFP- cells electroporated with Cas9-P2A-ZsGreen without guides that is the sample more 
similar to the wild type). There were not statistical differences between edited cells (I + II+) 
and any control, such as I + II- (GFP- fraction of cells electroporated with the guides), C+ and 
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C- (GFP+ and GFP– fractions of cells electroporated with the plasmid without guides). Also, 
there were no differences with respect to the non-electroporated cells (wt) and neither with 
the bone marrow CD34+ PKD cells differentiated from the patient bone marrow sample 
(Figure 43, A and C).  
Equally, the cell distribution from more immature II (CD36+/CD45mid) to more 
mature IV (CD36-/CD45-) cells did not show statistical differences. Despite the mean of 
subpopulation II of C+ was higher than the rest; it also had a huge dispersion meaning that 
there were no consistent differences (Figure 43, B and D).  
That lack of differences was also observed at the microscope. Both deficient (I + II+ 
and PKD) and control cells (I + II– and C) reached the stage in which most of the cells were 
orthochromatic erythroblasts (Figure 43, E, 2)  
Finally, PK/HK ratio was analyzed in in vitro differentiated cells to check if the RPK 
activity had been impaired by the gene editing protocol (Figure 44). 
 
Figure 44. PK/HK activity of edited cells after erythroid differentiation.  
Green circles: GFP+ fraction cells electroporated with the two guides from different experiments. Purple 
square:  PKD  cells  differentiated  from  patient  bone marrow  sample.  Red  triangles: mix  of  different 
control cells electroporated and sorted (GFP‐ of cell cultures electroporated with the two guides; GFP+ 
and GFP–  populations  of  cells  electroporated with  Cas9‐P2A‐ZsGreen without  guides). Measures  are 
normalized with respect of PK/HK of control samples, which were consider =1 (**** P<0.0001; n=6) 
Edited cells, I + II, reached PK/HK values comparable with the obtained in the in 
vitro differentiated PKD patient sample and significantly lower than the values obtained 
from control wt differentiated cells.  
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On the whole, it has been demonstrated that I + II cells had the expected DNA 
modification (Figure 42), that this modification impaired RPK production (Figure 39) and, 
despite cells were capable of differentiating along erythroid lineage (Figure 43), their PK/HK 
activity was as much compromised as on patient cells (Figure 44). Hence, I + II cells have 
demonstrated being a useful tool as new in vitro model to study the disease on human cells. 
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PKD patient features 
Analysis of PKD patient peripheral blood samples corroborated the main features 
described for the disease, such as RBC, hemoglobin and hematocrit decrease and MCV 
increase of patient´s RBC due to the egressing of immature RBC from bone marrow to 
compensate the anemia.48 
The use of a system such as ROC curves, based on the representation of true positive 
rate against false positive rate at different thresholds (understanding positive as PKD patient 
and negative as healthy donor), has been useful to set predictive values of hematological 
parameters (hemoglobin, RBC count, MCV, etc.) that permitted to define samples as PKD. 
The few PKD-relatives analyzed, despite they are not affected by the disease, showed a 
profile closer to PKD patients than to healthy donors. Nevertheless, relatives’ values remain 
within the healthy side of the thresholds set based on ROC curves, predicting them 
correctly as healthy. These thresholds are meant to distinguish PKD patients from their 
relatives and healthy donors but are not values for diagnosis. However, clinical values of 
hemoglobin levels considered anemic are 11-11.9 g/dL in women older than 15 years old 
and 10-12.9 g/dL in men older than 15 years old. The average of the clinical criteria (11.45 
g/dL) was below ROC curve threshold set for hemoglobin in PKD patients (12.35 g/dL).130 
ROC curves were also performed on flow cytometry panels for the characterization 
of the anemia compensatory mechanism. Before an anemic situation, bone marrow releases 
erythroid progenitors (CD71+ CD235a+) and reticulocytes trying to compensate deficient 
RBC function. This was observed on PKD patients but not in their relatives, meaning that 
having just one allele mutated does not decrease hematological traits enough to push bone 
marrow to an anemia response. In this case, ROC curves thresholds help to identify if the 
patient is anemic enough to trigger the bone marrow response. 
 However, the decrease of all these hematological parameters is common to other 
anemias, so they cannot be considered the only diagnostic criteria, but they are very useful 
to follow-up the progression of the disease.  
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Another altered value found in PKD samples was monocyte counts when they were 
estimated using the hematological counter. In spite of the dispersion, mean PKD values 
were statistical lower than control ones. It must be taken into account that hematological 
counter analyzes leukocyte subsets as a relative proportion of three population (monocytes, 
granulocytes and lymphocytes), meaning that the registered monocyte decrease can be 
because of a real reduction of this population or because of an increase in the absolute 
number of granulocytes and lymphocytes. This population was also evaluated by flow 
cytometry through the analysis of the CD14 surface marker and indeed, PKD CD14+ 
percentage was slightly lower than healthy values (5±2 vs. 7±3, mean±SD). Nonetheless, 
values were so disperse that they did not give a statistical relevance to this difference. The 
disparity of the two methods and the fact that monocytes decrease has not been described 
before in bibliography, make us think that the changes were probably the result of artifacts 
of the procedure used. Additional patients will be analyzed to clearly define this potential 
decrease of monocytes in PKD patients. Apart from monocytes, no alterations were found in 
immune system populations, matching with values described in the literature.48,51 
One of the hypotheses posed was that knowing the fact that the bone marrow reacts 
to anemia by increasing the fraction of reticulocytes in peripheral blood, it could also affect 
to more immature hematopoietic populations. In other words, if PKD anemia triggers an 
egress of stem hematopoietic progenitors that would be reflected in an increase of 
circulating CD34+. Percentages of CD34+ cells in peripheral blood samples of PKD patients 
were marginally higher than in healthy donors. Something similar happened in the CFU 
assay, with a minor increase of the colonies originated in the patient´s samples, but not 
statistically significant. Thus, although a clear tendency is observed, the effect is very mild. 
A possible explanation could be that only in the most severe cases PKD affects the most 
primitive subsets of the hematopoietic lineage, something that has been described in a few 
cases of PKD whose alterations led to misdiagnosis, being confused with congenital 
dyserythropoietic anemia.131 Again, higher number of healthy donors and patients, 
including severe cases, should be analyzed to clearly define this potential increase. 
Moreover, this increase of hematopoietic progenitors in peripheral blood could be also 
inducing the generation of new niches of extramedullary erythropoiesis since splenic and 
hepatic erythropoiesis has been described in few PKD cases. Most of these cases were 
limited to Amish communities, therefore, it would be interesting to evaluate the level of 
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primitive hematopoietic progenitors (CD34+ cells or CFU) in these population to study if 
there is a relationship between the levels of hematopoietic progenitors in the peripheral 
blood and levels of extramedullary hematopoiesis..51,132  
In any case, no impairments were demonstrated in PKD CD34+ capacity to generate 
CFUs. This has special relevance thinking in the eventual clinical trial protocol in which 
coRPK vector is going to be used. The planned clinical protocol is based on autologous 
transplant of ex vivo CD34+ corrected cells. PKD hematopoietic progenitor collection would 
be performed by bone marrow mobilization, thus, robustness of hematopoietic progenitors 
would facilitate this step. Moreover, if finally this slight increase of CD34+ cells in peripheral 
blood is demonstrated, it could make CD34+ collection phase even easier. 
Regarding the mutations-severity association, a recent PKD natural history study 
pointed out that double non-missense (NM/NM) mutation could indicate a more severe 
phenotype, while double missense (M/M) predicts a better prognosis.51 Data collected from 
the patient´s analysis followed the same tendency. However, the number of patients per 
group was not enough to evaluate these data statistically. Finally, no severity-gender 
association was found in the analyzed patients. 
Altogether, these data have allowed us to carry out a complete characterization of 
peripheral blood of PKD patients and to compare it with their own relatives and healthy 
donors.  
Towards gene therapy clinical trial for PKD  
As commented before, the set-up of the gene therapy clinical protocol and clinical 
trial for PKD requires the definition of important details, such as the amount of viral 
particles needed to cure the disease. This number depends directly on viral vector efficacy 
and engraftment capacity of the transduced hematopoietic progenitors and stem cells, and 
would be reflected by the number of transduced cells required to restore a healthy erythroid 
phenotype. This final outcome can be followed-up by measuring the VCNs present in the 
peripheral blood cells of the treated patients. Previous studies have pointed out the 
therapeutic threshold above 25% of corrected cells or above 1 VCN 79,124. We wanted to 
define the minimum number of coRPK vector copies per cell required to restore a healthy 
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phenotype in the PKD mouse model available in our laboratory. This was crucial to make 
feasible gene therapy for PKD.  
ROC curves were performed using hematological parameters of C57BL/6 mice as 
healthy reference and AcB55 mice as PKD. The criteria for the election of the thresholds 
generated with these ROC curves were to maximize the sensitivity (thresholds that includes 
the highest number of true positives) and also the specificity (thresholds that includes the 
lowest number of false positives). Setting these thresholds was useful to distinguish healthy 
and deficient mice due to that, even in these control mice, most of the parameters 
(erythrocyte blood count, hemoglobin, etc.) had overlapped healthy/deficient values. For 
other features, such as reticulocyte percentage and spleen weight, in which 
healthy/deficient values were clearly separated, standard deviation range was used as 
reference. 
Regarding the use of standard deviation of reticulocyte percentages as reference, it 
must be taken into account that all experiments performed in mice were based on 
conditioning and transplantation of corrected hematopoietic progenitors. After transplant, 
all mice had to reconstitute all hematopoiesis and showed an increase in reticulocyte count 
that tended to stabilize, including mice transplanted with healthy hematopoietic progenitors 
(unpublished data from the group). Thus, reticulocyte values of healthy controls (2-4%) 
were lower than the recently transplanted mice (10-20%), so ROC curve threshold for 
reticulocyte percentage based on non-transplanted healthy mice would considered deficient 
even mice transplanted with healthy control cells.  
The first experiment performed using two coRPK transduction rounds achieved a 
complete curation of the mice, restoring healthy values of PK activity at day 40. Moreover, 
after a year of follow-up there were no evidences of anemia, reaching almost healthy values 
of reticulocyte percentages. Indeed, VCNs obtained were at least 10 times higher than the 
therapeutic threshold stablished later on. In this experiment, VCNs obtained were very 
variable, ranging from 2 to 6, and not related to the MOI used. This variability could be due 
to the conditions used in the transduction protocol, like the use of two transduction rounds, 
or to the transplantation of low number of stem cells transduced. Nevertheless, all mice 
were above the therapeutic threshold intended.  
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The use of only one transduction round and double number of cells transplanted per 
mouse (1x106 instead 0.5x106) showed less variability in VCN with respect to MOIs used.  
Correlation of VCN with respect to reticulocyte percentage, the reference parameter 
to follow-up the progression of the disease in mice, permitted to stablish a narrow window 
between 0.2 and 0.3 coRPK copies per cell above which mice were able to overcome the 
disease. 
Similar results were obtained in other experimental series performed in our 
laboratory where a different approach was addressed (unpublished data). Instead of 
transplanting coRPK corrected cells, healthy syngeneic hematopoietic cells were used. Cells 
were transplanted in different proportions of wild type and PKD (from 5 to 100%). Thirty 
percent of healthy donor cells were needed to have a therapeutic effect and to correct the 
disease. Consistently, data obtained in both experimental series demonstrated that a 
minimum of 30% healthy or corrected cells was sufficient to compensate the disease, setting 
the threshold above which our gene therapy program should be successful. 
These VCN values are clearly lower when compared with the copies per cell 
achieved in clinical trials developed by other groups that work in hematopoietic diseases. 
For instance, in different studies conducted to treat β-thalassemia between 0.7-2.1 copies 
per cell were required and close to 1 copy per cell in another trial conducted for Wiskott-
Aldrich syndrome.133–136  
On the other hand, the therapeutic coRPK vector has demonstrated to be able to 
reach 1 VCN per cell at MOI 50 in the mouse model. Thus, optimized conditions able to 
reach 1 VCN in the human hematopoietic graft would ensure the therapeutic threshold and 
the feasibility of the gene therapy clinical trial for the treatment of PKD patients.  
Gene therapy has demonstrated being a feasible treatment for other hematological 
diseases133–137 and we are the first group trying to apply it to PKD. This will mean a new 
perspective for the most severe patients that are transfusion-dependent even after 
splenectomy and whose only current curative alternative is allogenic bone marrow 
transplantation. 
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Human PKD modelling 
As it has been previously commented, the study of gene therapy and gene editing 
approaches to treat PKD had a main drawback, the lack of hematopoietic progenitors from 
patients. The target cell type for these therapies would be obtained from PKD bone marrow 
samples, but this sampling is too invasive and it is not part of the follow-up of PKD patients. 
To overcome this lack of PKD progenitor cells, two molecular strategies were carried out to 
generate PKD-like cells modifying healthy CD34+ progenitors.  
Regarding the generation of PKD-like cells by specific shRNAs, it was demonstrated 
that the three vectors tested were effective decreasing RPK protein levels in K562 cell line, 
especially Sh1. More importantly, the activity of the RPK protein, measured as the ratio 
PK/HK at the end of the differentiation protocol, was reduced up to 50% when compared 
with non-interfered cells, demonstrating the efficacy of the Sh1 viral vector to induce a 
PKD-like phenotype. However, surface antigen expression profile of the different 
erythroblast populations along the in vitro differentiation protocol did not show specific 
differences in the RPK interfered cells (Sh1+) when compared with either the differentiated 
cells after transduction with the Scrb vector or the Sh1- cells, the cells generated in the same 
culture coming from non-transduced progenitors. In the same way, the in vitro erythroid 
differentiation of CD34+ cells of a patient sample (see Generation of PKD-like cells using 
CRISPR/Cas9 section), as well as the PKD-like cells generated with the CRISPR/Cas9 system 
showed that pyruvate kinase deficient cells did not present differences in the antigen 
expression profile along in vitro differentiation in comparison with normal cells. These 
results demonstrate that the lack of RPK does not impaired the in vitro differentiation 
profile and that the only way to study RPK inhibition is by analyzing the functional activity 
of the RPK protein. 
Two unexpected limitations were found regarding inhibition of the RPK expression 
by shRNAs transduced with lentiviral vectors that compromised the use of this approach as 
model. The first one was the low transduction efficacy of Sh1 vector, which varied from 2 to 
20% depending of the experiment and of differential vector batch efficacy (5 different 
batches were used). The second unexpected limitation was the apparent decrease of the 
EGFP positive population over time on both Scrb and Sh1 transduced cells, resulting in a 
differential growing rate between transduced and non-transduced cells. The use of shRNA 
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lentiviral vectors seemed to slow down cell growth and differentiation towards erythroid 
lineage. The fact that these differences were also found in cells transduced with the Scrb 
vector indicates that this impairment was not due to a specific silencing of PKLR gene. 
Furthermore, the RPK protein starts to be crucial at polychromatophilic/orthochromatic 
stages, which only occurs at the end of erythroid differentiation protocol, meaning that the 
effect could be more related to the viral vector used. This unspecific growth arrest has not 
been reported with shRNAs under H1 promoter (like the used in this work) but it was 
observed with shRNAs under U6 promoter.138 A possible explanation to this effect is an 
innate interferon-mediated response probably triggered by the presence of dsRNAs. Other 
authors showed that this response could be dependent on slight differences in the shRNA 
sequences, making some of them more prone to initiate an immune response.139 
It is also important to remark that cells transduced with the shRNAs and with the 
therapeutic vector (coRPK) were able to produce the transgenic protein, meaning that any 
developed shRNA recognized coRPK mRNA, as expected because all the shRNAs had 3 
mismatches with respect to the codon optimized sequence, or because the level of 
expression of the transgene was too high to be silenced by Sh1.  
Altogether, despite the growth issues found along in vitro differentiation protocol, 
the Sh1 lentiviral vector showed a high and very specific capacity to silence RPK gene 
expression. Unfortunately, the low number of PKD-like cells generated in these cultures 
limited its potential use as a human source of PKD-like hematopoietic progenitors.  
As a second strategy, we developed a genome editing approach to knock-out the 
PKLR gene. This strategy was possible thanks to the development of highly efficient 
engineered nucleases that induce double strand breaks in specific sites of the genome.112–115 
This strategy has been demonstrated feasible even in primary cells.140–142 Here, we have 
applied the CRISPR/Cas9 system for this purpose.  
The use of genome editing to model diseases can also resemble specific mutations 
found in patients. This fact will facilitate the study of specific mutations and the potential 
genotype-phenotype association. Herein, we have focused our genome editing events on 
mutations found in PKD patients.143 Exons 8, 9 and 11 were studied since these exons have 
the highest mutations burden in PKD patients, being the tools developed for exon 9 the 
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most efficient in terms of gene editing. In fact, all treated cells, selected by the expression of 
GFP, present in the construct expressing the different elements of the CRISPR/Cas9 system, 
were properly edited in the selected genome site. This efficient gene editing was obtained in 
different stablished cell lines as well as in primary human hematopoietic progenitors 
(CD34+), showing this strategy optimal and closer to patient cells. 
Again, a significant toxicity was observed in primary cells when these tools were 
used. The most common and less toxic delivery method used to introduce CRISPR/Cas9 is 
electroporating as ribonucleoprotein.144 Unfortunately, this strategy did not permitt the 
enrichment of the edited cells having a mix of wt and PKD-like cells at the end of the 
experiments insufficient to be considered a good model. The use of DNA as delivery method 
was conditioned by the necessity to select edited cells by GFP because modified cells cannot 
be phenotypically distinguished from wt cells at the end of the differentiation. A possible 
solution for this could be the use of the recently commercialized Cas9-GFP fusion proteins. 
If sorting of cells electroporated with these ribonucleoprotein complexes really represents 
edited cells, it will solve both problems. 
The use of guides separately resulted in the classical indel distribution around cut 
site.116 However, the use of guides in pairs turned out as a good strategy to control the events 
generated. This strategy has already been used by others.145–147 In our case, after using two 
guides at the same time, about 70% events generated were the expected precise deletion, 
something correlating with some reported data145, but almost twice the obtained by 
others.146,147 This idea of controlling events was especially interesting in the combination of 
guide I+II (also named combo 2) that only generated two main events, something not 
previously reported, the expected 31 bp deletion and a very similar deletion of 32 bp. Both 
events generated premature stop codons, making this combination perfect to have a PKD-
like model of predictable genotype. Also, the generation of a BstXI restriction site was useful 
to follow the presence of the precise deletion. However, precise deletion was not possible in 
Combo 1 (8 bp deletion) because the sequences of both guides overlapped, thus cleavage 
activity of guide I altered recognition site of the other guide. 
 Other possible outcomes described in the literature are the activity of both guides of 
each couple acting separately but not generating the deletion, named here as single guide 
indel (SGI), or acting at the same time generating inversions or duplications.148 All these 
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kinds of events would be present in amplicons with similar sizes to the wild type sequence. 
NGS study of small deletions (such as combos 1 and 2) permitted the finding of SGI using 
the same mapping used to study the deletions. However, combos 3 to 6 generated deletions 
too big to use this strategy. For this, to find SGI in the rest of the combos, two NGS mapping 
were performed, one of them assuming the wild type sequence as template and the other 
using the theoretical deletion as template. As it has been showed, SGI events were found in 
combos 3 to 6. Additional experiments would be required to find inversions or duplications 
as long as NGS software cannot map sequences too different from the given template.  
Selection of exon 9 as gene editing target has demonstrated to be a good choice to 
knock out RPK, as long as all combinations tested, that start in this exon, resulted in the 
complete elimination of RPK protein. This means that the modification of this region is 
important, corroborating the in silico study. Also, the use of a GFP labeled Cas9 to select the 
cells in which gene editing tools were introduced was a highly efficient procedure.  
Regarding the capacity to mature toward erythroid lineage, as commented in the 
previous section, the PKD patient sample was able to reach orthochromatic stage during in 
vitro differentiation, not showing cell accumulation in any immature stage that could 
indicate defects in maturation. This supports the idea of PKD cells differentiate in vitro as 
normal cells, without altering the erythroid surface antigen profile. PKD-like cells 
generated by CRISPR/Cas9 resembled perfectly this capacity and also presented the decrease 
of PK activity characteristic of PKD. Again, the PK activity in this differentiated cells, 
measured by PK/HK ratio resemble the activity found in the patient differentiated cells. 
On the whole, the generation of PKD-like cells with the guide combination I+II 
allowed us to generate a model with a known genotype that perfectly reflects the main in 
vitro features of the PKD cells. This is a very useful tool where evaluate the feasibility of the 
different gene therapy and gene editing strategies to cure the disease. 
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1. The loss of one PKLR functional allele (as relatives have) decreases erythroid 
parameters but not enough to reach an anemic situation. 
2. An increase in erythroid progenitor population (detectable by its CD71+ CD235a+ 
immunophenotype) and in reticulocytes appear in peripheral blood samples of PKD 
patients as a response of the bone marrow to the anemic stress. 
3. A small, although not significant, increase of hematopoietic progenitors is observed 
in peripheral blood of PKD patients. 
4. CD34+ hematopoietic cells from PKD patients do not show impairments in 
progenitor’s content or in their differentiation ability, an important feature because 
this cell type will be the source for the production of the medicinal product for the 
PKD gene therapy clinical trial. 
5. Mice transplanted with cells transduced with the therapeutic vector rescue from the 
deficient phenotype when VCN values in peripheral blood are higher than 0.3. 
6. PKD-like cells generated by the transduction of CD34+ hematopoietic progenitors 
with specific RPK-shRNA decrease PK activity but also undergo vector-induced cell 
growth alterations. 
7. All mutations generated in K562 cell line with CRISPR/Cas9 tools along exon 9, 
intron 9 and exon 10 of PKLR gene completely eliminate RPK protein production, 
showing the importance of this region for enzyme generation. 
8. The use of guides in couples to direct Cas9 activity generate predictable precise 
deletion pattern as the most represented event in cell lines and primary cells, 
making the use of guide pairs a good strategy to control the outcomes of the genome 
editing process.  
9. Precise deletion is consistently recorded in all deletions sizes generated, ranging 
from 30 to 490 bp. 
10. Human PKD-like cells generated from CD34+ hematopoietic progenitors using 
CRISPR/Cas9 reproduce the characteristics of PKD hematopoietic cells, PK activity 
decreased and no alterations along in vitro erythroid differentiation being, 
therefore, an appropriated model to test new advanced therapies for PKD. 
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